000136591612/312021Q1FALSEP5Y91100013659162021-01-012021-03-31xbrli:shares00013659162021-05-04iso4217:USD00013659162021-03-3100013659162020-12-31iso4217:USDxbrli:shares0001365916us-gaap:ProductMember2021-01-012021-03-310001365916us-gaap:ProductMember2020-01-012020-03-310001365916amrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMember2020-01-012020-03-3100013659162020-01-012020-03-310001365916us-gaap:PreferredStockMember2020-12-310001365916us-gaap:CommonStockMember2020-12-310001365916us-gaap:AdditionalPaidInCapitalMember2020-12-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001365916us-gaap:RetainedEarningsMember2020-12-310001365916us-gaap:NoncontrollingInterestMember2020-12-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-12-310001365916amrs:MezzanineEquityCommonStockMember2020-12-310001365916us-gaap:CommonStockMember2021-01-012021-03-310001365916us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2021-01-012021-03-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-01-012021-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001365916us-gaap:RetainedEarningsMember2021-01-012021-03-310001365916us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001365916us-gaap:PreferredStockMember2021-03-310001365916us-gaap:CommonStockMember2021-03-310001365916us-gaap:AdditionalPaidInCapitalMember2021-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001365916us-gaap:RetainedEarningsMember2021-03-310001365916us-gaap:NoncontrollingInterestMember2021-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2021-03-310001365916amrs:MezzanineEquityCommonStockMember2021-03-310001365916us-gaap:PreferredStockMember2019-12-310001365916us-gaap:CommonStockMember2019-12-310001365916us-gaap:AdditionalPaidInCapitalMember2019-12-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001365916us-gaap:RetainedEarningsMember2019-12-310001365916us-gaap:NoncontrollingInterestMember2019-12-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2019-12-310001365916amrs:MezzanineEquityCommonStockMember2019-12-310001365916us-gaap:CommonStockMember2020-01-012020-03-310001365916us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-01-012020-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001365916us-gaap:RetainedEarningsMember2020-01-012020-03-310001365916us-gaap:PreferredStockMember2020-03-310001365916us-gaap:CommonStockMember2020-03-310001365916us-gaap:AdditionalPaidInCapitalMember2020-03-310001365916us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001365916us-gaap:RetainedEarningsMember2020-03-310001365916us-gaap:NoncontrollingInterestMember2020-03-310001365916amrs:TotalEquityExcludingMezzanineEquityMember2020-03-310001365916amrs:MezzanineEquityCommonStockMember2020-03-3100013659162019-12-3100013659162020-03-310001365916amrs:KoninklijkeDSMNVDSMMember2021-01-012021-03-310001365916amrs:KoninklijkeDSMNVDSMMember2020-01-012020-03-3100013659162010-09-272021-03-310001365916us-gaap:MachineryAndEquipmentMember2021-03-310001365916us-gaap:MachineryAndEquipmentMember2020-12-310001365916us-gaap:LeaseholdImprovementsMember2021-03-310001365916us-gaap:LeaseholdImprovementsMember2020-12-310001365916amrs:ComputerEquipmentAndSoftwareMember2021-03-310001365916amrs:ComputerEquipmentAndSoftwareMember2020-12-310001365916amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember2021-03-310001365916amrs:FurnitureAndOfficeEquipmentVehiclesAndLandMember2020-12-310001365916us-gaap:ConstructionInProgressMember2021-03-310001365916us-gaap:ConstructionInProgressMember2020-12-310001365916srt:MinimumMember2021-03-310001365916srt:MaximumMember2021-03-31xbrli:pure0001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:SeniorConvertibleNotesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueMeasurementsRecurringMember2021-03-310001365916us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916us-gaap:FairValueMeasurementsRecurringMember2020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2021-03-310001365916amrs:ForisConvertibleNoteMemberamrs:MeasurementInputStockPriceMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:MeasurementInputProbabilityOfChangeInControlMemberamrs:ForisConvertibleNoteMemberus-gaap:ConvertibleDebtMember2020-03-310001365916amrs:ForisConvertibleNoteMember2021-01-012021-03-310001365916amrs:ForisConvertibleNoteMemberus-gaap:ConvertibleDebtMember2021-03-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916amrs:MeasurementInputStockPriceMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputDiscountRateMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916amrs:MeasurementInputProbabilityOfChangeInControlMemberus-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-03-310001365916us-gaap:LongTermDebtMember2020-12-310001365916us-gaap:LongTermDebtMember2021-01-012021-03-310001365916us-gaap:LongTermDebtMember2021-03-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2020-12-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2021-01-012021-03-310001365916us-gaap:FairValueInputsLevel3Memberamrs:DerivativeLiabilityDebtRelatedMember2021-03-310001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2020-02-280001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2020-02-282020-02-280001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2021-03-310001365916amrs:WarrantsIssuedInConnectionWithSeptember2019AndNovember2019ShottenfeldNotesMember2021-01-012021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputSharePriceMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputSharePriceMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputExercisePriceMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputExercisePriceMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputExercisePriceMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-310001365916srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2021-03-310001365916srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2021-03-310001365916srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001365916srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2020-12-310001365916us-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001365916us-gaap:MeasurementInputExpectedDividendRateMember2020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2020-01-012020-12-310001365916us-gaap:ConvertibleDebtMember2021-03-310001365916us-gaap:ConvertibleDebtMember2021-01-012021-03-310001365916us-gaap:ConvertibleDebtMember2020-12-310001365916us-gaap:ConvertibleDebtMember2020-01-012020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2021-01-012021-03-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2020-12-310001365916amrs:ForisConvertibleNoteMemberamrs:RelatedPartyConvertibleNotesMember2020-01-012020-12-310001365916amrs:RelatedPartyConvertibleNotesMember2021-03-310001365916amrs:RelatedPartyConvertibleNotesMember2021-01-012021-03-310001365916amrs:RelatedPartyConvertibleNotesMember2020-12-310001365916amrs:RelatedPartyConvertibleNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:SchottenfeldNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:NikkoNotesMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:GinkgoCollaborationNoteMember2020-01-012020-12-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2021-03-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2021-01-012021-03-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2020-12-310001365916us-gaap:LoansPayableMemberamrs:OtherLoansPayableMember2020-01-012020-12-310001365916us-gaap:LoansPayableMember2021-03-310001365916us-gaap:LoansPayableMember2021-01-012021-03-310001365916us-gaap:LoansPayableMember2020-12-310001365916us-gaap:LoansPayableMember2020-01-012020-12-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:ForisDebtMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:TheNaxyrisLoanAgreementMemberamrs:RelatedPartyLoanPayableMember2020-01-012020-12-310001365916amrs:RelatedPartyLoanPayableMember2021-03-310001365916amrs:RelatedPartyLoanPayableMember2021-01-012021-03-310001365916amrs:RelatedPartyLoanPayableMember2020-12-310001365916amrs:RelatedPartyLoanPayableMember2020-01-012020-12-3100013659162020-01-012020-12-310001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-02-040001365916us-gaap:ConvertibleDebtMemberamrs:NewSeniorConvertibleNotesDue2022Member2021-02-042021-02-040001365916amrs:SchottenfeldSeptember2019CreditAgreementsMember2021-03-0100013659162021-03-012021-03-010001365916amrs:DSMCreditAgreementMember2017-12-280001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2017-12-280001365916amrs:DSMCreditAgreementMember2017-12-282017-12-280001365916amrs:The2019DSMCreditAgreementMemberamrs:DSMInternationalBVMember2019-09-17amrs:installment00013659162019-09-170001365916amrs:DSMCreditAgreementMember2019-09-170001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2019-09-170001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentRelatedTo25MillionDollarNoteMember2021-01-012021-03-310001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentMember2021-03-310001365916us-gaap:UnsecuredDebtMemberamrs:DSMCreditAgreementMarch2021AmendmentMember2021-01-012021-03-310001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2021-01-012021-03-310001365916amrs:DSMCreditAgreementMemberus-gaap:UnsecuredDebtMember2021-03-310001365916amrs:LoansPayableAndCreditFacilitiesMember2021-03-310001365916amrs:RelatedPartyLoansPayableAndCreditFacilitiesMember2021-03-310001365916amrs:GatesFoundationPurchaseAgreementMember2021-03-310001365916amrs:GatesFoundationPurchaseAgreementMember2021-01-012021-03-310001365916amrs:HighTrailSilverbackWarrantsMember2021-03-310001365916amrs:January2020WarrantExerciseRightSharesMember2021-03-310001365916amrs:April2019PIPEWarrantsMember2021-03-310001365916srt:MinimumMemberamrs:April2019PIPEWarrantsMember2021-03-310001365916srt:MaximumMemberamrs:April2019PIPEWarrantsMember2021-03-310001365916amrs:NaxyrisLSAWarrantsMember2021-03-310001365916amrs:October2019NaxyrisWarrantMember2021-03-310001365916amrs:May20196.50NoteExchangeWarrantsMember2021-03-310001365916amrs:May2017CashWarrantsMember2021-03-310001365916amrs:May2017DilutionWarrantsMember2021-03-310001365916amrs:August2017DilutionWarrantsMember2021-03-310001365916amrs:July2015RelatedPartyDebtExchange3Member2021-03-310001365916amrs:OtherMember2021-03-310001365916amrs:PeriodEndCommonStockWarrantsMember2021-01-012021-03-310001365916amrs:PeriodEndCommonStockWarrantsMember2020-01-012020-03-310001365916amrs:ConvertiblePromissoryNotesMember2021-01-012021-03-310001365916amrs:ConvertiblePromissoryNotesMember2020-01-012020-03-310001365916amrs:StockOptionsToPurchaseCommonStockMember2021-01-012021-03-310001365916amrs:StockOptionsToPurchaseCommonStockMember2020-01-012020-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001365916amrs:PeriodEndPreferredSharesMember2021-01-012021-03-310001365916amrs:PeriodEndPreferredSharesMember2020-01-012020-03-310001365916amrs:AprinnovaJVMember2021-03-310001365916us-gaap:ProductMembercountry:US2021-01-012021-03-310001365916country:USamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916country:USamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916country:US2021-01-012021-03-310001365916us-gaap:ProductMembercountry:US2020-01-012020-03-310001365916country:USamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916country:USamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916country:US2020-01-012020-03-310001365916us-gaap:ProductMembersrt:EuropeMember2021-01-012021-03-310001365916srt:EuropeMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916srt:EuropeMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916srt:EuropeMember2021-01-012021-03-310001365916us-gaap:ProductMembersrt:EuropeMember2020-01-012020-03-310001365916srt:EuropeMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916srt:EuropeMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916srt:EuropeMember2020-01-012020-03-310001365916srt:AsiaMemberus-gaap:ProductMember2021-01-012021-03-310001365916srt:AsiaMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916srt:AsiaMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916srt:AsiaMember2021-01-012021-03-310001365916srt:AsiaMemberus-gaap:ProductMember2020-01-012020-03-310001365916srt:AsiaMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916srt:AsiaMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916srt:AsiaMember2020-01-012020-03-310001365916country:BRus-gaap:ProductMember2021-01-012021-03-310001365916country:BRamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916country:BRamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916country:BR2021-01-012021-03-310001365916country:BRus-gaap:ProductMember2020-01-012020-03-310001365916country:BRamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916country:BRamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916country:BR2020-01-012020-03-310001365916amrs:OtherAreaMemberus-gaap:ProductMember2021-01-012021-03-310001365916amrs:OtherAreaMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:OtherAreaMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:OtherAreaMember2021-01-012021-03-310001365916amrs:OtherAreaMemberus-gaap:ProductMember2020-01-012020-03-310001365916amrs:OtherAreaMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:OtherAreaMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:OtherAreaMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:ConsumerMember2021-01-012021-03-310001365916amrs:ConsumerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:ConsumerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:ConsumerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:ConsumerMember2020-01-012020-03-310001365916amrs:ConsumerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:ConsumerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:ConsumerMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:IngredientCustomerMember2021-01-012021-03-310001365916amrs:IngredientCustomerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:IngredientCustomerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:IngredientCustomerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:IngredientCustomerMember2020-01-012020-03-310001365916amrs:IngredientCustomerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:IngredientCustomerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:IngredientCustomerMember2020-01-012020-03-310001365916us-gaap:ProductMemberamrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:LicensesAndRoyaltiesMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916us-gaap:ProductMemberamrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:LicensesAndRoyaltiesMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMemberamrs:GrantsAndCollaborationsMember2020-01-012020-03-310001365916amrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:SephoraMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SephoraMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:SephoraMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SephoraMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:FirmenichMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GivaudanInternationalSaMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GivaudanInternationalSaMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GivaudanInternationalSaMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMemberamrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2021-01-012021-03-310001365916amrs:RenewableProductsMemberamrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:LicensesAndRoyaltiesMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:GrantsAndCollaborationsMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:AllOtherCustomersMemberamrs:SignificantRevenueAgreementMember2020-01-012020-03-310001365916amrs:RenewableProductsMember2021-01-012021-03-310001365916amrs:RenewableProductsMember2020-01-012020-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMembersrt:MaximumMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:DSMLicenseAgreementMemberamrs:FinishedGoodsInventoryMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:ReceivablesMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:IntellectualPropertyLicenseMemberamrs:DSMLicenseAgreementMember2021-03-310001365916amrs:DSMInternationalBVMemberus-gaap:LicenseMemberamrs:DSMLicenseAgreementMember2021-01-012021-03-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2017-12-012017-12-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2017-12-310001365916amrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMemberamrs:DSMPerformanceCollabrationMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMember2021-01-012021-03-310001365916amrs:DSMIngredientsCollaborationMemberamrs:DSMInternationalBVMemberamrs:ResearchAndDevelopmentCustomerMember2020-01-012020-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMember2021-01-012021-03-310001365916amrs:YifanMemberamrs:GrantsAndCollaborationsMember2021-03-3100013659162021-04-012021-03-3100013659162022-01-012021-03-3100013659162023-01-012021-03-3100013659162024-01-012021-03-310001365916amrs:ForisNotesMemberamrs:RelatedPartyDebtMemberamrs:ForisVenturesLLCMember2021-03-310001365916amrs:ForisNotesMemberamrs:RelatedPartyDebtMemberamrs:ForisVenturesLLCMember2020-12-310001365916amrs:DSMNoteMemberamrs:RelatedPartyDebtMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:DSMNoteMemberamrs:RelatedPartyDebtMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:NaxyrisSAMemberamrs:RelatedPartyDebtMemberamrs:NaxyrisNoteMember2021-03-310001365916amrs:NaxyrisSAMemberamrs:RelatedPartyDebtMemberamrs:NaxyrisNoteMember2020-12-310001365916amrs:RelatedPartyDebtMember2021-03-310001365916amrs:RelatedPartyDebtMember2020-12-310001365916amrs:AccountsReceivableUnbilledRelatedPartyMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:AccountsReceivableUnbilledRelatedPartyMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:ContractAssetsRelatedPartyMemberamrs:DSMInternationalBVMember2021-03-310001365916amrs:ContractAssetsRelatedPartyMemberamrs:DSMInternationalBVMember2020-12-310001365916amrs:DSMInternationalBVMemberamrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember2021-03-310001365916amrs:DSMInternationalBVMemberamrs:AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesMember2020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001365916us-gaap:RestrictedStockUnitsRSUMember2021-03-310001365916us-gaap:CostOfSalesMember2021-01-012021-03-310001365916us-gaap:CostOfSalesMember2020-01-012020-03-310001365916us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001365916us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-310001365916us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001365916us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001365916us-gaap:EmployeeStockOptionMember2021-03-310001365916us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001365916amrs:A2020EquityIncentivePlanMember2021-03-310001365916amrs:EquityIncentivePlan2010Member2021-03-310001365916amrs:PublicStockOfferingSharesFromSellingStockholdersMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingSharesFromSellingStockholdersMemberus-gaap:SubsequentEventMember2021-04-080001365916amrs:PublicStockOfferingSharesFromAmyrisMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916us-gaap:SubsequentEventMember2021-04-080001365916us-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingSellingStockholdersUnderUnderwritingAgreementMemberus-gaap:SubsequentEventMember2021-04-082021-04-080001365916amrs:PublicStockOfferingAmyrisUnderUnderwritingAgreementMemberus-gaap:SubsequentEventMember2021-04-082021-04-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

-OR-
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-34885

AMYRIS, INC.
(Exact name of registrant as specified in its charter) 
Delaware
55-0856151
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
(510) 450-0761
(Address and telephone number of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share AMRS The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

Shares outstanding of the Registrant's common stock:
Class
Outstanding as of May 4, 2021
Common Stock, $0.0001 par value per share
291,471,055




AMYRIS, INC.
TABLE OF CONTENTS

Page
PART I
Item 1.
3
3
4
5
6
7
10
Item 2.
29
Item 3.
35
Item 4.
36
PART II
Item 1.
37
Item 1A.
37
Item 2.
38
Item 3.
38
Item 4.
38
Item 5.
38
Item 6.
39



2



PART I
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
AMYRIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except shares and per share amounts) March 31,
2021
December 31, 2020
Assets
Current assets:
Cash and cash equivalents $ 143,821  $ 30,152 
Restricted cash 283  309 
Accounts receivable, net of allowance of $154 and $137, respectively
27,036  32,846 
Accounts receivable - related party, net of allowance of $0 and $0, respectively
391  12,110 
Contract assets 6,589  4,178 
Contract assets - related party 2,000  1,203 
Inventories 47,639  42,862 
Deferred cost of products sold - related party 5,220  9,801 
Prepaid expenses and other current assets 19,246  13,103 
Total current assets 252,225  146,564 
Property, plant and equipment, net 31,933  32,875 
Deferred cost of products sold, noncurrent - related party 9,391  9,939 
Restricted cash, noncurrent 961  961 
Recoverable taxes from Brazilian government entities 8,680  8,641 
Right-of-use assets under financing leases, net 9,296  9,994 
Right-of-use assets under operating leases, net 9,333  10,136 
Other assets 4,770  3,704 
Total assets $ 326,589  $ 222,814 
Liabilities, Mezzanine Equity and Stockholders' Deficit
Current liabilities:
Accounts payable $ 44,154  $ 41,045 
Accrued and other current liabilities 32,121  30,707 
Financing lease liabilities 3,258  4,170 
Operating lease liabilities 5,510  5,226 
Contract liabilities 6,163  4,468 
Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively)
55,904  54,748 
Related party debt, current portion —  22,689 
Total current liabilities 147,110  163,053 
Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)
13,873  26,170 
Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively)
413,687  159,452 
Operating lease liabilities, net of current portion 8,209  9,732 
Derivative liabilities 31,384  8,698 
Other noncurrent liabilities 22,467  22,754 
Total liabilities 636,730  389,859 
Commitments and contingencies
Mezzanine equity: Contingently redeemable common stock 5,000  5,000 
Stockholders’ deficit:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,280 shares issued and outstanding as of March 31, 2021 and December 31, 2020
—  — 
Common stock - $0.0001 par value, 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively
27  24 
Additional paid-in capital 2,106,214  1,957,224 
Accumulated other comprehensive loss (49,413) (47,375)
Accumulated deficit (2,377,943) (2,086,692)
Total Amyris, Inc. stockholders’ deficit (321,115) (176,819)
Noncontrolling interest 5,974  4,774 
Total stockholders' deficit (315,141) (172,045)
Total liabilities, mezzanine equity and stockholders' deficit $ 326,589  $ 222,814 

See the accompanying notes to the unaudited condensed consolidated financial statements.


3



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended March 31,
(In thousands, except shares and per share amounts) 2021 2020
Revenue:
Renewable products (includes related party revenue of $1,662 and $49, respectively)
$ 28,179  $ 17,854 
Licenses and royalties (includes related party revenue of $143,612, and $3,750, respectively)
143,800  5,161 
Grants and collaborations (includes related party revenue of $2,000 and $3,018, respectively)
4,880  6,115 
Total revenue (includes related party revenue of $147,274 and $6,817, respectively)
176,859  29,130 
Cost and operating expenses:
Cost of products sold 22,659  11,790 
Research and development 23,332  17,126 
Sales, general and administrative 37,922  32,014 
Total cost and operating expenses 83,913  60,930 
Income (loss) from operations 92,946  (31,800)
Other income (expense):
Interest expense (5,813) (15,002)
(Loss) gain from change in fair value of derivative instruments (22,745) 3,282 
Loss from change in fair value of debt (326,785) (16,503)
Loss upon extinguishment of debt (27,313) (27,319)
Other (expense) income, net (678)
Total other expense, net (383,334) (55,538)
Loss before income taxes and loss from investment in affiliate (290,388) (87,338)
Provision for income taxes (55) (91)
Gain (loss) from investment in affiliate 392  (415)
Net loss (290,051) (87,844)
Less: income attributable to noncontrolling interest in Aprinnova (1,200) — 
Net loss attributable to Amyris, Inc. (291,251) (87,844)
Less: losses allocated to participating securities 2,099  1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (289,152) $ (86,757)
Loss per share attributable to common stockholders, basic and diluted $ (1.08) $ (0.56)
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted 267,733,555  155,065,635 

See the accompanying notes to the unaudited condensed consolidated financial statements.


4




AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

Three Months Ended March 31,
(In thousands) 2021 2020
Comprehensive loss:
Net loss $ (290,051) $ (87,844)
Foreign currency translation adjustment (2,038) (2,549)
Total comprehensive loss (292,089) (90,393)
Income attributable to noncontrolling interest (1,200) — 
Comprehensive loss attributable to Amyris, Inc. $ (293,289) $ (90,393)

See the accompanying notes to the unaudited condensed consolidated financial statements.


5



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT AND MEZZANINE EQUITY
(Unaudited)

Preferred Stock Common Stock
(In thousands, except number of shares) Shares Amount Shares Amount Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Noncontrolling Interest Total Stockholders' Deficit Mezzanine Equity - Common Stock
Balances at December 31, 2020 8,280  $ —  244,951,446  $ 24  1,957,224  $ (47,375) $ (2,086,692) $ 4,774  $ (172,045) $ 5,000 
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock —  —  496,341  —  (2) —  —  —  (2) — 
Issuance of common stock upon conversion of debt principal, net of 2,600,000 pre-delivery shares returned to Amyris
—  —  5,827,164  110,574  —  —  —  110,575  — 
Issuance of common stock upon exercise of stock options —  —  377,542  —  1,920  —  —  —  1,920  — 
Issuance of common stock upon exercise of warrants —  —  15,557,480  32,217  —  —  —  32,219  — 
Issuance of common stock upon exercise of warrants - related party —  —  6,056,944  —  —  —  —  —  —  — 
Stock-based compensation —  —  —  —  4,281  —  —  —  4,281  — 
Foreign currency translation adjustment —  —  —  —  (2,038) —  —  (2,038) — 
Net loss attributable to Amyris, Inc. —  —  —  —  —  $ (291,251) $ 1,200  (290,051) — 
Balances at March 31, 2021 8,280  $ —  273,266,917  $ 27  $ 2,106,214  $ (49,413) $ (2,377,943) $ 5,974  $ (315,141) $ 5,000 
Balances at December 31, 2019 8,280  $ —  117,742,677  $ 12  1,543,668  $ (43,804) $ (1,755,653) $ 609  $ (255,168) $ 5,000 
Issuance of common stock and warrants upon conversion of debt principal and accrued interest —  —  6,337,594  21,259  —  —  —  21,260  — 
Issuance of common stock in private placement —  —  3,484,321  —  10,000  —  —  —  10,000  — 
Issuance of common stock in private placement - related party —  —  10,505,652  27,188  —  —  —  27,189  — 
Issuance of common stock upon exercise of warrants —  —  1,160,929  —  3,332  —  —  —  3,332  — 
Issuance of common stock upon exercise of warrants - related party —  —  24,165,166  68,763  —  —  —  68,765  — 
Exercise of common stock rights warrant - related party —  —  —  —  15,000  —  —  —  15,000  — 
Issuance of common stock right warrant - related party —  —  —  —  8,904  —  —  —  8,904  — 
Modification of previously issued common stock warrants —  —  —  —  1,286  —  —  —  1,286  — 
Derecognition of liability warrants to equity —  —  —  —  5,200  —  —  —  5,200  — 
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock —  —  495,581  —  (8) —  —  —  (8) — 
Stock-based compensation —  —  —  —  3,504  —  —  —  3,504  — 
Foreign currency translation adjustment —  —  —  —  —  (2,549) —  —  (2,549) — 
Net loss attributable to Amyris, Inc. —  —  —  —  —  —  (87,844) —  (87,844) — 
Balances at March 31, 2020 8,280  $ —  163,891,920  $ 16  $ 1,708,096  $ (46,353) $ (1,843,497) $ 609  $ (181,129) $ 5,000 

See the accompanying notes to the unaudited condensed consolidated financial statements.


6



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


7



Three Months Ended March 31,
(In thousands) 2021 2020
Operating activities
Net loss $ (290,051) $ (87,844)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss from change in fair value of debt 326,785  16,503 
Loss upon extinguishment of debt 27,313  27,319 
(Gain) loss from change in fair value of derivative instruments 22,745  (3,282)
Stock-based compensation 4,281  3,504 
Depreciation and amortization 2,114  1,719 
Amortization of right-of-use assets under operating leases 750  668 
Accretion of debt discount 713  1,292 
(Gain) loss on foreign currency exchange rates 408  (109)
Other —  42 
(Gain) loss from investment in affiliate (392) 415 
Changes in assets and liabilities:
Accounts receivable 17,275  (5,209)
Contract assets (3,208) (870)
Inventories (5,686) (4,392)
Deferred cost of products sold - related party 5,129  142 
Prepaid expenses and other assets (8,207) (1,430)
Accounts payable 4,154  318 
Accrued and other liabilities 4,011  4,009 
Lease liabilities (1,185) (1,043)
Contract liabilities 1,702  1,873 
Net cash provided by (used in) operating activities 108,651  (46,375)
Investing activities
Purchases of property, plant and equipment (2,493) (1,040)
Net cash used in investing activities (2,493) (1,040)
Financing activities
Issuance costs incurred in connection with debt modification (2,500) — 
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units (2) (8)
Principal payments on debt (23,196) (6,981)
Principal payments on financing leases (912) (866)
Proceeds from exercise of common stock rights warrant - related party —  15,000 
Proceeds from exercises of common stock options 1,920  — 
Proceeds from exercises of warrants 32,219  3,332 
Proceeds from exercises of warrants - related party —  13,998 
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs —  10,000 
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party —  15,000 
Proceeds from issuance of debt, net of issuance costs —  188 
Net cash provided by financing activities 7,529  49,663 
Effect of exchange rate changes on cash, cash equivalents and restricted cash (44) 19 
Net increase in cash, cash equivalents and restricted cash 113,643  2,267 
Cash, cash equivalents and restricted cash at beginning of period 31,422  1,699 
Cash, cash equivalents and restricted cash at end of the period $ 145,065  $ 3,966 
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents $ 143,821  $ 2,607 
Restricted cash, current 283  399 
Restricted cash, noncurrent 961  960 
Total cash, cash equivalents and restricted cash $ 145,065  $ 3,966 

See the accompanying notes to the unaudited condensed consolidated financial statements.


8



AMYRIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued
(Unaudited)

Three Months Ended March 31,
(In thousands) 2021 2020
Supplemental disclosures of cash flow information:
Cash paid for interest $ 3,275  $ 3,152 
Supplemental disclosures of non-cash investing and financing activities:
Accrued interest added to debt principal $ —  $ 1,527 
Derecognition of derivative liabilities to equity upon extinguishment of debt $ 59  $ — 
Derecognition of derivative liabilities upon exercise of warrants $ —  $ 5,200 
Exercise of common stock warrants in exchange for debt principal and accrued interest reduction $ —  $ 69,918 
Fair value of embedded features in connection with private placement $ —  $ 2,962 
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances $ —  $ 188 
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party $ —  $ 747 
Issuance of common stock and warrants upon conversion of debt principal and accrued interest $ 110,575  $ 18,333 
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period $ 1,121  $ 1,307 

See the accompanying notes to the unaudited condensed consolidated financial statements.


9



AMYRIS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)


1. Basis of Presentation and Summary of Significant Accounting Policies

As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, Amyris, Inc. and our subsidiaries (collectively, Amyris or the Company) apply the Company's proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. The Company does so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that the Company manufactures at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, the Company has successfully developed, produced and commercialized many distinct molecules.

The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the 2020 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2020 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Significant Accounting Policies

Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2020 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2021.

Use of Estimates and Judgements

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant


10



accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.

Accounting Standards or Updates Recently Adopted

In the three months ended March 31, 2021, the Company adopted these accounting standards or updates:

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Accounting Standards or Updates Not Yet Adopted

Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

2. Balance Sheet Details

Allowance for Doubtful Accounts
(In thousands) Balance at Beginning of Year Provisions Write-offs, Net Balance at End of Period
Three months ended March 31, 2021 $ 137  $ 17  $ —  $ 154 
Three months ended March 31, 2020 $ 45  $ —  $ —  $ 45 

Inventories
(In thousands) March 31, 2021 December 31, 2020
Raw materials $ 12,185  $ 11,800 
Work-in-process 8,702  10,760 
Finished goods 26,752  20,302 
Inventories $ 47,639  $ 42,862 

Deferred cost of products sold - related party


11



(In thousands) March 31, 2021 December 31, 2020
Deferred cost of products sold - related party $ 5,220  $ 9,801 
Deferred cost of products sold, noncurrent - related party 9,391  9,939 
Total $ 14,611  $ 19,740 

Amounts reported as "Deferred cost of products sold - related party" are in connection with an agreement with Koninklijke DSM N.V. (DSM) under which DSM will provide capacity for sweetener production at DSM's Brotas, Brazil manufacturing facility through December 2022. Deferred cost of products sold asset is being expensed to cost of products sold on a units of production basis as the Company's sweetener product is sold over the five-year term of the supply agreement. During the three months ended March 31, 2021 and 2020, the Company expensed $1.6 million and $0.1 million, respectively, of the deferred cost of products sold asset to cost of products sold. Inception-to-date amortization through March 31, 2021 totaled $4.9 million.

Prepaid expenses and other current assets
(In thousands) March 31, 2021 December 31, 2020
Prepayments, advances and deposits $ 13,453  $ 6,637 
Non-inventory production supplies 3,364  3,989 
Recoverable taxes from Brazilian government entities 1,020  1,063 
Other 1,409  1,414 
Total prepaid expenses and other current assets $ 19,246  $ 13,103 

Property, Plant and Equipment, Net
(In thousands) March 31, 2021 December 31, 2020
Machinery and equipment $ 49,880  $ 50,415 
Leasehold improvements 44,800  45,197 
Computers and software 7,362  6,741 
Furniture and office equipment, vehicles and land 3,450  3,507 
Construction in progress 7,238  7,250 
112,730  113,110 
Less: accumulated depreciation and amortization (80,797) (80,235)
Property, plant and equipment, net $ 31,933  $ 32,875 

During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows:
Three Months Ended March 31,
(In thousands) 2021 2020
Depreciation and amortization expense $ 2,114  $ 1,719 

Leases

Operating Leases

The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 5 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $9.3 million and $10.1 million of right-of-use assets as of March 31, 2021 and December 31, 2020, respectively. Operating lease liabilities were $13.7 million and $15.0 million as of March 31, 2021 and December 31, 2020, respectively. During the three


12



ended March 31, 2021 and 2020, respectively, the Company recorded $1.8 million and $1.5 million of operating lease amortization that was charged to expense, of which $0.2 million and $0.3 million was recorded to cost of products sold.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component.

Information related to the Company's right-of-use assets and related lease liabilities were as follows:
Three Months Ended March 31,
2021 2020
Cash paid for operating lease liabilities, in thousands $1,185 $1,893
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $— $—
Weighted-average remaining lease term 2.7 3.2
Weighted-average discount rate 18.0% 18.0%

Financing Leases

The Company has financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $5.3 million and $4.6 million as of March 31, 2021 and December 31, 2020, respectively.

Maturities of Financing and Operating Leases

Maturities of lease liabilities as of March 31, 2021 were as follows:
Years ending December 31:
(In thousands)
Financing
Leases
Operating
Leases
Total Leases
2021 (Remaining Nine Months) $ 3,491  $ 5,644  $ 9,135 
2022 —  7,655  7,655 
2023 —  3,320  3,320 
2024 —  150  150 
2025 —  —  — 
Total lease payments 3,491  16,769  20,260 
Less: amount representing interest (233) (3,050) (3,283)
Total lease liability $ 3,258  $ 13,719  $ 16,977 
Current lease liability $ 3,258  $ 5,510  $ 8,768 
Noncurrent lease liability —  8,209  8,209 
Total lease liability $ 3,258  $ 13,719  $ 16,977 

Other Assets
(In thousands) March 31, 2021 December 31, 2020
Equity-method investment $ 3,431  $ 2,380 
Deposits 126  128 
Other 1,213  1,196 
Total other assets $ 4,770  $ 3,704 



13



Accrued and Other Current Liabilities
(In thousands) March 31, 2021 December 31, 2020
Payroll and related expenses $ 10,540  $ 8,230 
Accrued interest 7,721  9,327 
Contract termination fees 5,311  5,344 
Asset retirement obligation(1)
3,003  3,041 
Professional services 1,604  994 
Ginkgo partnership payments obligation 878  878 
Tax-related liabilities 639  656 
Other 2,425  2,237 
Total accrued and other current liabilities $ 32,121  $ 30,707 
______________
(1)    The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.


Other noncurrent liabilities
(In thousands) March 31, 2021 December 31, 2020
Liability for unrecognized tax benefit $ 7,551  $ 7,496 
Ginkgo partnership payments obligation, net of current portion 7,461  7,277 
Liability in connection with acquisition of equity-method investment 7,216  6,771 
Contract liabilities, net of current portion 111  111 
Other 128  1,099 
Total other noncurrent liabilities $ 22,467  $ 22,754 




14



3. Fair Value Measurement

Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy:

(In thousands) March 31, 2021 December 31, 2020
Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total
Liabilities
Foris Convertible Note (LSA Amendment) $ —  $ —  $ 379,439  $ 379,439  $ —  $ —  $ 123,164  $ 123,164 
Senior Convertible Notes —  —  54,757  54,757  —  —  53,387  53,387 
Embedded derivatives bifurcated from debt instruments —  —  188  188  —  —  247  247 
Freestanding derivative instruments issued in connection with other debt and equity instruments —  —  31,196  31,196  —  —  8,451  8,451 
Total liabilities measured and recorded at fair value $ —  $ —  $ 465,580  $ 465,580  $ —  $ —  $ 185,249  $ 185,249 

The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. Also, there were no transfers between the levels during the three months ended March 31, 2021 or the year ended December 31, 2020.

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates.

Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments".

Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt".

Fair Value of Debt — Foris Convertible Note

At March 31, 2021, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $379.4 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 10% discount yield, (iii) 0.09% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. The Company recorded a loss of $256.3 million related to change in fair value of the Foris Convertible Note for the three months ended March 31, 2021. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price.

Fair Value of Debt — Senior Convertible Notes

At March 31, 2021, the contractual outstanding principal of the Senior Convertible Notes was $10.0 million, and fair value was $54.8 million. The Company measured the fair value at March 31, 2021 under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 210% discount yield, (iii) 0.02% risk free interest rate (iv) 45% equity volatility, and (v) 0% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.50 conversion price.

For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows:


15



In thousands
Fair value at December 31, 2020 $ 53,387 
Loss from change in fair value 70,510 
Less: principal converted into common stock (20,000)
Less: fair value adjustment extinguished upon conversion of debt principal (49,140)
Fair value at March 31, 2021 $ 54,757 

Binomial Lattice Model

A binomial lattice model was used to determine whether the Foris Convertible Note and the Senior Convertible Notes (Debt Instruments) would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Debt Instruments using the "with-and-without method", where the fair value of the Debt Instruments including the embedded and freestanding features is defined as the "with," and the fair value of the Debt Instruments excluding the embedded and freestanding features is defined as the "without." This method estimates the fair value of the Debt Instruments by looking at the difference in the values of the Debt Instruments with the embedded and freestanding derivatives and the fair value of the Debt Instruments without the embedded and freestanding features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Debt Instruments and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period.

Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments

The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3):
(In thousands) Derivative Liability
Balance at December 31, 2020 $ 8,698 
Change in fair value of derivative instruments 22,745 
Derecognition on settlement or extinguishment (59)
Balance at March 31, 2021 $ 31,384 

Freestanding Derivative Instruments

On February 28, 2020, the Company entered into forbearance agreements with certain affiliates of the Schottenfeld Group LLC (the Lenders) related to certain defaults under the Schottenfeld Notes. In connection with entering into the forbearance agreements, the Company committed to issuing warrants (Warrants) to the Lenders under certain contingent events for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The contingent obligation to issue the Warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability and remeasured each reporting period until settled or extinguished with subsequent changes in fair value recorded through the statement of operations. The fair value of the Warrants derivative liability was determined using a Black-Scholes-Merton option pricing model based on the input assumptions for liability classified warrants table in the valuation methodology section below. At March 31, 2021, the fair value of the contingently issuable Warrants derivative liability was $31.2 million, and for the three months ended March 31, 2021, the Company recorded a $22.7 million loss on change in fair value of derivative instruments.

Valuation Methodology and Approach to Measuring the Derivative Liabilities

Substantially all the outstanding liabilities associated with the Company’s derivatives at March 31, 2021 and December 31, 2020 represent the fair value of freestanding equity instruments. See Note 4, "Debt", and Note 6, "Stockholders' Deficit" for further information regarding these host instruments. There is no current observable market for these types of


16



derivatives and, as such, the Company determined the fair value of the freestanding instruments using the Black-Scholes-Merton option pricing model, which is discussed in more detail below.

The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2021 and December 31, 2020. Input assumptions for these freestanding instruments are as follows:
Range for the Period
Input assumptions for liability classified warrants: March 31, 2021 December 31, 2020
Fair value of common stock on issue date
$19.10 – $19.10
$2.56 – $6.18
Exercise price of warrants
$2.87 – $2.87
$2.87 – $3.25
Expected volatility
114% – 114%
94% – 117%
Risk-free interest rate
0.16% – 0.16%
0.13% – 1.58%
Expected term in years
2 – 2
1 – 2
Dividend yield 0.0  % 0.0 %

Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields term to maturity/conversion or stock price volatility increases the value of the derivative liability.

Assets and Liabilities Recorded at Carrying Value

Financial Assets and Liabilities

The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2021 and at December 31, 2020, excluding the debt instruments recorded at fair value, was $49.3 million and $86.5 million, respectively. The fair value of such debt at March 31, 2021 and at December 31, 2020 was $51.1 million and $83.3 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.


17




4. Debt

Net carrying amounts of debt are as follows:
March 31, 2021 December 31, 2020
(In thousands) Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net
Convertible notes payable
Senior convertible notes $ 10,020  $ —  $ 44,737  $ 54,757  $ 30,020  $ —  $ 23,367  $ 53,387 
Related party convertible notes payable
Foris convertible note 50,041  —  329,398  379,439  50,041  —  73,123  123,164 
Loans payable and credit facilities
Schottenfeld notes —  —  —  —  12,500  (240) —  12,260 
Nikko notes 2,737  (725) —  2,012  2,802  (759) —  2,043 
Ginkgo note 12,000  —  —  12,000  12,000  —  —  12,000 
Other loans payable 1,009  —  —  1,009  1,227  —  —  1,227 
15,746  (725) —  15,021  28,529  (999) —  27,530 
Related party loans payable
Foris note 5,000  —  —  5,000  5,000  —  —  5,000 
DSM notes 10,000  (4,254) —  5,746  33,000  (2,443) —  30,557 
Naxyris note 23,914  (412) —  23,502  23,914  (493) —  23,421 
38,914  (4,666) —  34,248  61,914  (2,936) —  58,978 
Total debt $ 114,721  $ (5,391) $ 374,135  483,465  $ 170,504  $ (3,935) $ 96,490  263,059 
Less: current portion (55,904) (77,437)
Long-term debt, net of current portion $ 427,561  $ 185,622 

Senior Convertible Notes Conversion

On February 4, 2021, the Company received a notice of conversion from HT Investments MA, LLC (HT) with respect to $20.0 million of its outstanding Senior Convertible Notes, pursuant to which the Company was required to issue 5.7 million shares of common stock per the conversion price stated in the agreement and cancelled the outstanding Note. Also, under the terms of the Senior Convertible Note, HT was required to return 2.6 million shares of common stock outstanding under the Pre-Delivery Shares provision once the Company had fully repaid the principal balance. HT fulfilled its obligation to return these shares in accordance with the contractual requirement, and as a result the Company net settled the $20 million principal conversion by issuing 3.1 million of incremental shares to HT.

Upon conversion of the HT Senior Convertible Note, the Company recorded a $31.9 million loss upon extinguishment of debt, which was primarily comprised of a fair value adjustment upon repayment of the note's principal.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Senior Convertible Notes.

Schottenfeld Note Exchange

On March 1, 2021, the Company entered into an Exchange and Settlement Agreement (Exchange Agreement) with Schottenfeld Opportunities Fund II, L.P. and certain other holders of notes under the Credit and Security Agreement dated November 14, 2019 (Schottenfeld Notes). Pursuant to the terms of the Exchange Agreement, the Company paid all accrued and unpaid interest on the $12.5 million principal balance outstanding under the Schottenfeld Notes, and issued 4.1 million net shares of common stock in a cashless exchange and cancellation of all amounts due and outstanding under the Notes and related loan documents and all warrants held by each of the holders of Schottenfeld Notes.

Upon conversion of the Schottenfeld note balance, the Company recorded a $28.9 million loss upon extinguishment of debt, which primarily represented the fair value of common shares issued in excess of debt principal extinguished.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Schottenfeld Notes.


18




DSM Notes Amendments and Repayment

On December 28, 2017, the Company and DSM Finance, a wholly owned subsidiary of Koninklijke DSM N.V. (DSM), entered into a credit agreement (the DSM Credit Agreement) to make available to the Company an unsecured credit facility of $25.0 million. On December 28, 2017, the Company borrowed $25.0 million under the DSM Credit Agreement and issued a promissory note to DSM Finance. The $25 million Note matures on December 31, 2021 and accrues interest at 10% per annum, payable quarterly.

On September 17, 2019, the Company and DSM entered into a credit agreement (the 2019 DSM Credit Agreement) to make available to the Company a secured credit facility in an aggregate principal amount of $8.0 million. In September 2019, the Company borrowed the $8.0 million in three installments. The promissory notes issued under the 2019 DSM Credit Agreement (i) mature on August 7, 2022, (ii) accrue interest at a rate of 12.5% per annum, payable quarterly and (iii) are secured by a first-priority lien on certain Company intellectual property licensed to DSM.

In March 2021, the Company entered into amendments (the March 2021 Amendments) to the $25 million Note and the $8 million Note that provided for (i) the prepayment of the $8 million Note, (ii) a $15 million partial prepayment of the $25 million Note and (iii) extension of the maturity date from December 31, 2021 to April 15, 2022 for the remaining $10 million principal balance under the $25 million Note, in exchange for a $2.5 million prepayment fee The Company repaid $23 million on March 31, 2021 to extinguish the $8 million Note and to partially repay the $25 million Note.

The Company evaluated the March 2021 Amendments, and concluded the before and after cash flows resulting from the amendments were not significantly different and accounted for the amendments to the Notes as a debt modification. Consequently, the $2.5 million Prepayment Fee was recorded as an incremental debt discount to the remaining $10 million principal balance under the $25 million Note. The Company will accrete the adjusted discount over the Note’s amended remaining term using the effective interest method.

See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the DSM notes.

Future Minimum Payments

Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows:
(In thousands) Convertible Notes Loans
Payable and Credit Facilities
Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total
2021 (Remaining Nine Months) $ 11,189  $ 2,260  $ —  $ 2,782  $ 16,231 
2022 —  13,268  59,578  42,379  115,225 
2023 —  399  —  —  399 
2024 —  398  —  —  398 
2025 —  397  —  —  397 
Thereafter —  1,473  —  —  1,473 
Total future minimum payments 11,189  18,195  59,578  45,161  134,123 
Less: amount representing interest (1,169) (2,449) (9,537) (6,247) (19,402)
Present value of minimum debt payments 10,020  15,746  50,041  38,914  114,721 
Less: current portion of debt principal (10,020) (1,280) —  —  (11,300)
Noncurrent portion of debt principal $ —  $ 14,466  $ 50,041  $ 38,914  $ 103,421 

5. Mezzanine Equity

Mezzanine equity at March 31, 2021 and December 31, 2020 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults in its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a


19



third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%.

As of March 31, 2021, the Company's remaining research and development obligation under this arrangement was $0.3 million.

6. Stockholders' Deficit

Warrants and Rights Activity Summary

In connection with various debt and equity transactions (see Note 4, “Debt” above and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2020 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2021:
Transaction Number Outstanding as of March 31, 2021 Exercise Price per Share as of March 31, 2021
Blackwell and Silverback warrants 1,000,000  $ 3.25 
January 2020 warrant exercise right shares 4,209,608  $ 2.87 
April 2019 PIPE warrants 1,381,940 
$4.76/$5.02
Naxyris LSA warrants 2,000,000  $ 2.87 
October 2019 Naxyris warrant 2,000,000  $ 3.87 
May 2019 6.50% Note Exchange warrants 960,225  $ 2.87 
May 2017 cash warrants 1,863,056  $ 2.87 
May 2017 dilution warrants 3,085,893  $ 0.00 
August 2017 dilution warrants 3,028,983  $ 0.00 
July 2015 related party debt exchange 58,690  $ 0.15 
Other 1,406  $ 160.05 
19,589,801 

Warrant Exercises

During the three months ended March 31, 2021, warrant-holders exercised warrants to purchase approximately 24.8 million shares of the Company’s common stock at a weighted-average exercise price of $3.06 per share, for net proceeds to the Company of $32.2 million. Some of the exercises were cashless or in connection with the Schottenfeld Note Exchange, which resulted in fewer shares being issued than the number of warrant-shares exercised. As a result, 21.6 million shares were issued.

7. Net Loss per Share Attributable to Common Stockholders

For the three months ended March 31, 2021 and 2020, basic loss per share was the same as diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive.

The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses.


20




The following table presents the calculation of basic and diluted loss per share:
Three Months Ended March 31,
(In thousands, except shares and per share amounts) 2021 2020
Numerator:
Net loss attributable to Amyris, Inc. $ (291,251) $ (87,844)
Less: losses allocated to participating securities 2,099  1,087 
Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (289,152) $ (86,757)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 267,733,555  155,065,635 
Loss per share, basic and diluted $ (1.08) $ (0.56)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive:
Three Months Ended March 31,
2021 2020
Period-end common stock warrants 13,416,235  50,518,519 
Convertible promissory notes(1)
19,540,447  9,217,185 
Period-end stock options to purchase common stock 6,205,576  5,578,264 
Period-end restricted stock units 6,653,640  5,298,639 
Period-end preferred stock 1,943,661  1,943,661 
Total potentially dilutive securities excluded from computation of diluted loss per share 47,759,559  72,556,268 
______________
(1)    The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

8. Commitments and Contingencies

Guarantor Arrangements

The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2021 and December 31, 2020.

The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM and the Company's shares of Aprinnova. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note.

The obligations of the Company under the Naxyris Note (see Note 4, "Debt") are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement.

The Nikko $3.9 million note is collateralized by a first-priority lien on 10.0% of the Aprinnova JV interests owned by the Company.


21




Other Matters

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. By May 10, 2021, the derivative shareholder plaintiffs will either file a new complaint or designate one of the existing complaints as operative. A briefing schedule on a demurrer to that complaint will be negotiated no later than May 24, 2021. The Company believes the securities class action and derivative complaints lack merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters.

On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). Amyris filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The matter is fully briefed and the parties are awaiting an order from the Court. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom.

The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s


22



expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.

9. Revenue Recognition and Contract Assets and Liabilities

Disaggregation of Revenue

The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer:
Three Months Ended March 31,
(In thousands) 2021 2020
Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total
United States $ 20,090  $ —  $ 250  $ 20,340  $ 11,944  $ —  $ —  $ 11,944 
Europe 2,972  143,800  2,346  149,118  3,242  5,161  3,356  11,759 
Asia 4,405  2,284  6,689  2,018  —  2,759  4,777 
Brazil 313  313  577  —  —  577 
Other 399  399  73  —  —  73 
$ 28,179  $ 143,800  $ 4,880  $ 176,859  $ 17,854  $ 5,161  $ 6,115  $ 29,130 

The following table presents revenue by major product and service, as well as by customer type:
Three Months Ended March 31,
(In thousands) 2021 2020
Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total
Consumer $ 15,653  $ —  $ —  $ 15,653  $ 9,065  $ —  $ —  $ 9,065 
Ingredients 12,526  143,800  —  156,326  8,789  5,161  —  13,950 
Research and development —  —  4,880  4,880  —  —  6,115  6,115 
$ 28,179  $ 143,800  $ 4,880  $ 176,859  $ 17,854  $ 5,161  $ 6,115  $ 29,130 

Revenue from Significant Revenue Agreements

In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
(In thousands) 2021 2020
Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total
DSM - related party $ 1,662  $ 143,612  $ 2,000  $ 147,274  $ 49  $ 3,750  $ 3,018  $ 6,817 
Sephora 4,441  —  —  4,441  4,446  —  —  4,446 
Yifan —  —  2,284  2,284  —  —  2,709  2,709 
Firmenich 379  188  205  772  1,229  1,411  161  2,801 
Givaudan 210  —  —  210  2,109  —  —  2,109 
Subtotal revenue from significant revenue agreements 6,692  143,800  4,489  154,981  7,833  5,161  5,888  18,882 
Revenue from all other customers 21,487  —  391  21,878  10,021  —  227  10,248 
Total revenue from all customers $ 28,179  $ 143,800  $ 4,880  $ 176,859  $ 17,854  $ 5,161  $ 6,115  $ 29,130 

DSM License Agreement and Contract Assignment

On March 31, 2021, the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property (F&F Intellectual Property License) of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain


23



commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. The Company and DSM also entered into a 15-year manufacturing agreement whereby the Company will manufacture certain F&F ingredients for DSM to supply to third parties.

The Company determined the licenses to be functional intellectual property licenses allowing DSM the immediate use of and benefit from the technology, and concluded the licenses and related assigned F&F ingredients supply agreements, the asset purchase agreement and the manufacturing agreement were revenue contracts within the scope of ASC 606. The Company identified three distinct performance obligations: (i) F&F license, (ii) finished goods inventory and (iii) receivables, that once delivered are satisfied at a point in time. The Company also concluded the additional contingent consideration and manufacturing supply agreement represent variable consideration that will be fully constrained until the commercial targets are probable of achievement and the products are manufactured and sold.

The Company allocated the $150 million transaction price to the three revenue performance obligations using the residual approach. The transaction price was first allocated to the transferred inventory and receivables at the stand-alone selling price for these performance obligations, and the residual consideration was allocated to the F&F intellectual property licenses:
Finished goods inventory - $1.5 million
Receivables - $4.9 million
F&F intellectual property licenses - $143.6 million

The Company also concluded the F&F intellectual property licenses and the assigned F&F supply agreements had been fully delivered with no further performance obligation upon closing the transaction, and recognized license revenue of $143.6 million in the period ended March 31, 2021.

Due to the related party nature of the transaction with DSM, who is a significant shareholder with two members on the Company’s board of directors, the Company performed a fair value assessment of the F&F intellectual property licenses under an income approach using a discounted cash flow model, in part with the assistance of a third-party valuation firm, and concluded the $143.6 million residual consideration received in exchange for the F&F intellectual property licenses approximated the fair value and stand-alone selling price of the F&F intellectual property licenses.

DSM Performance Agreement

In December 2017, the Company and DSM entered into a research and development services agreement (Performance Agreement), pursuant to which the Company would provide services to DSM relating to the further development of the technology underlying farnesene-related products in exchange for certain bonus payments in the event that specific performance metrics were achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. The Company accounted for the Performance Agreement under ASC 606 as a combined transaction with the Farnesene license granted to DSM in connection with the sale of the Brotas facility in December 2017. The Performance Agreement was allocated $1.2 million of the transaction price under a relative fair value allocation approach, and was recorded as a contract asset reflecting the Company’s right to receive additional consideration and deferred revenue reflecting the probability of returning to DSM a portion of the cash received under the combined transaction. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated. As a result, the Company paid DSM $1.9 million and reduced the deferred revenue liability, and expensed the contract asset balance and recorded $1.9 million of additional research and development expense during the three months ended March 31, 2021.

DSM Ingredients Collaboration

Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from October 1, 2020 to September 30, 2021 for services singularly focused on achieving a certain fermentation yield and cost target over the twelve-month period. During the three months ended March 31, 2021 and 2020, the Company recognized $2.0 million and $3.0 million of collaboration revenue in connection with the amended agreement.



24



Yifan Collaborations

The Company has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. (Yifan), a leading Chinese pharmaceutical company. During the three months ended March 31, 2021 and 2020, the Company recognized $2.3 million and $2.7 million of collaboration revenue, and $16.6 million of cumulative-to-date collaboration revenue in connection with the agreement. At March 31, 2021, the Company also recorded a $5.9 million contract asset in connection with the Collaboration Agreement.

For more information about the DSM ingredients collaboration and Yifan collaboration, see the Company's 2020 Form 10-K, Part II, Item 8, Note 10, "Revenue Recognition".

Contract Assets and Liabilities

When a contract results in revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional.

Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer.

Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company.

Contract Balances

The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers:
(In thousands) March 31, 2021 December 31, 2020
Accounts receivable, net $ 27,036  $ 32,846 
Accounts receivable - related party, net $ 391  $ 12,110 
Contract assets $ 6,589  $ 4,178 
Contract assets - related party $ 2,000  $ 1,203 
Contract liabilities $ 6,163  $ 4,468 
Contract liabilities, noncurrent(1)
$ 111  $ 111 

(1)As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.

Remaining Performance Obligations

The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021.
(In thousands) As of March 31, 2021
Remaining 2021 $ 143 
2022 3,103 
2023 1,430 
2024 and thereafter 429 
Total from all customers $ 5,105 

In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual


25



property. Additionally, approximately $297.8 million of estimated future revenue is excluded from the table above, as that amount represents constrained variable consideration.

10. Related Party Transactions

Related Party Debt

See Note 4, "Debt," for details of the DSM Notes Amendments and Repayments that occurred during the three months ended March 31, 2021.

Related party debt was as follows:
March 31, 2021 December 31, 2020
In thousands Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net
Foris notes $ 55,041  $ —  $ 329,398  $ 384,439  $ 55,041  $ —  $ 73,123  $ 128,164 
DSM notes 10,000  (4,254) —  5,746  33,000  (2,443) —  30,557 
Naxyris note 23,914  (412) —  23,502  23,914  (493) —  23,421 
$ 88,955  $ (4,666) $ 329,398  $ 413,687  $ 111,955  $ (2,936) $ 73,123  $ 182,142 

Related Party Revenue

See Note 9, "Revenue Recognition", for information about the March 31, 2021 DSM License Agreement and Contract Assignment.

Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable

Related party accounts receivable, contract assets and accounts payable were as follows:

(In thousands) March 31, 2021 December 31, 2020
Accounts receivable - related party $ 391  $ 12,110 
Contract assets - related party $ 2,000  $ 1,203 
Accounts payable $ 10,302  $ 5,011 

11. Stock-based Compensation

The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Stock Options Weighted-
average
Exercise
Price
Weighted-average
Remaining
Contractual
Life, in Years
Aggregate
Intrinsic
Value, in Thousands
Outstanding - December 31, 2020 6,502,096  $ 7.64  7.6 $ 8,875 
Granted 131,408  $ 14.52 
Exercised (375,390) $ 5.12 
Forfeited or expired (52,538) $ 38.21 
Outstanding - March 31, 2021 6,205,576  $ 7.68  7.4 $ 82,615 
Vested or expected to vest after March 31, 2021 5,697,447  $ 7.91  7.3 $ 75,493 
Exercisable at March 31, 2021 1,259,029  $ 18.19  5.8 $ 12,884 



26



The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows:
Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years
Outstanding - December 31, 2020 7,043,909  $ 4.18  1.5
Awarded 345,903  $ 13.53 
Released (496,492) $ 4.34 
Forfeited (239,680) $ 4.22 
Outstanding - March 31, 2021 6,653,640  $ 4.65  1.4
Vested or expected to vest after March 31, 2021 6,082,165  $ 4.65  1.3

Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows:
Three Months Ended March 31,
(In thousands) 2021 2020
Cost of products sold $ 63  $ — 
Research and development 1,062  1,065 
Sales, general and administrative 3,156  2,439 
Total stock-based compensation expense $ 4,281  $ 3,504 

As of March 31, 2021, there was unrecognized compensation expense of $30.0 million related to stock options and RSUs. The Company expects to recognize this expense over a weighted-average period of 2.4 years.

Evergreen Shares for 2020 Equity Incentive Plan and 2010 Employee Stock Purchase Plan

In March 2021, the Board approved increases to the number of shares available for issuance under the Company's 2020 Equity Incentive Plan (the 2020 Equity Plan) and 2010 Employee Stock Purchase Plan (the 2010 ESPP).

The increase in shares in connection with the 2020 Equity Plan represented an automatic annual increase in the number of shares available for grant and issuance under the 2020 Equity Plan of 12,247,572 shares (Evergreen Shares). This increase is equal to approximately 5.0% of the 244,951,446 total outstanding shares of the Company’s common stock as of December 31, 2020. This automatic increase was effective as of January 1, 2021.

The increase in shares in connection with the 2010 ESPP represented an automatic annual increase in the number of shares reserved for issuance of 42,077 shares, which represents the remaining allowable under the existing 1,666,666 maximum limit for share issuance under the 2010 ESPP. This automatic increase was effective as of January 1, 2021.

12. Subsequent Events

Primary and Secondary Offering

On April 8, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Cowen and Company, LLC (the Underwriters) and with certain stockholders of the Company (the Selling Stockholders), pursuant to which the Selling Stockholders agreed to sell 11,390,797 shares of common stock of the Company, par value $0.0001 per share and Amyris agreed to issue and sell 7,656,822, at a public offering price of $15.75 per share. DSM International B.V. and affiliates of Vivo Capital LLC were the Secondary Offering Selling Stockholders. Under the terms of the Underwriting Agreement, the Selling Stockholders and Amyris granted the Underwriters a 30-day option to purchase up to an additional 1,708,619 shares of Common Stock from the Selling Stockholders and 1,148,523 shares of Common Stock from Amyris. The Underwriters exercised this option in full.

Net proceeds to the Company from the 8,805,345 new shares issued by the Company were approximately $130.7 million (inclusive of the underwriters’ option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.


27




The Company did not receive any proceeds from the sale of common stock in the secondary offering by the Selling Stockholders.

Ingredion Agreement

On May 3, 2021, the Company and Ingredion Incorporated entered into a Membership Interest Purchase Agreement (MIPA) under which (i) the Company will assign and transfer certain contracts for the sale and distribution of RebM to Ingredion’s subsidiary, PureCircle, which will become the exclusive global business-to-business commercialization partner for the Company’s sugar reduction technology that includes fermented RebM; (ii) the Company and Ingredion will enter into certain intellectual property license agreements to make, have made, commercialize and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners and potentially other types of fermentation-based ingredients; (iii) Ingredion will purchase 31% of all of the membership interests in Amyris RealSweet LLC, a wholly owned subsidiary of the Company incorporated on April 15, 2021 (RealSweet), which entity will own the new manufacturing facility under construction in Brazil, and; (iv) The parties will enter into an R&D collaboration agreement to create and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners, and potentially other types of fermentation-based food ingredients. The Company will continue to own and market its Purecane™ consumer brand offering of tabletop and culinary sweetener products to consumers. Under the terms of the license agreement, the Company will receive an upfront $10 million license fee at closing and additional milestone payments in the aggregate of $35 million upon achievement of certain manufacturing cost targets and RebM sales revenue. The Company will also receive $30 million of cash and non-cash consideration from Ingredion in exchange for their 31% interest in RealSweet. Additionally, the Company will earn a profit share from future Reb M sales by PureCircle. The closing of the MIPA is subject to customary closing conditions.



28




ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q. These discussions contain forward-looking statements reflecting our current expectations that involve risks and uncertainties which are subject to safe harbors under the Securities Act of 1933, as amended (the Securities Act), and the Securities Exchange Act of 1934 (the Exchange Act). These forward-looking statements include, but are not limited to, statements concerning our strategy of achieving a significant reduction in net cash outflows in 2021 and 2022, aspects of our future operations, our future financial position, expectations for our future revenues, margins and projected costs, expectations regarding demand and acceptance for our technologies and products, introductions of new products, growth opportunities and trends in the market in which we operate, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the 2020 Form 10-K) and in our other filings with the Securities and Exchange Commission. We do not assume any obligation to update any forward-looking statements.

Overview

As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, we apply our proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. We do so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. Our biotechnology platform enables us to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that we manufacture at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, we have successfully developed, produced and commercialized thirteen distinct molecules used in formulations by thousands of leading global brands.

We believe that synthetic biology represents a third industrial revolution, bringing together biology and engineering to generate new, more sustainable materials to meet the growing global demand for bio-based replacements of petroleum-based and traditional animal- or plant-derived ingredients. We continue to generate demand for our current portfolio of products through an extensive go-to-market network provided by our partners that are the leading companies in our target markets. Via our partnership model, our partners invest in the development of molecules to take it from the lab to commercial scale and use their extensive marketing and sales capabilities to sell our ingredients and formulations to their customers. We capture long-term revenue both through the production and sale of our molecules to our partners and through royalty revenues from our partners' product sales to their customers. We have also successfully formulated our unique, natural and sustainably-sourced ingredients into wholly-owned consumer brands, including Biossance® our clean beauty skincare brand, Pipette®, our baby and mother care brand, and PurecaneTM, our alternative sweetener brand. We are marketing our brands directly to consumers via our ecommerce platforms, in brick-and-mortar stores, and online via various retail partners.

We were founded in 2003 in the San Francisco Bay area by a group of scientists from the University of California, Berkeley. Through a grant in 2005 from the Bill & Melinda Gates Foundation, we developed technology capable of creating microbial strains that produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug.

We produced a renewable farnesene brand, Biofene®, a long-chain, branched hydrocarbon molecule that we manufacture through fermentation using engineered microbes. Our farnesene derivatives are sold in hundreds of products as nutraceuticals, skincare products, fragrances, solvents, polymers, and lubricant ingredients. In 2014, we began manufacturing additional molecules for the Flavor & Fragrance industry; in 2015, we began investing to expand our capabilities to other small molecule chemical classes via our collaboration with the Defense Advanced Research Projects Agency (DARPA); and in 2016, we expanded into proteins. We then made the strategic decision to transition our business model from low margin commodity markets to higher margin specialty ingredients markets. We began the transition by first commercializing and supplying farnesene-derived squalane as a cosmetic ingredient to formulators and distributors. We also entered into collaboration and supply agreements for the development and commercialization of molecules within the Flavor & Fragrance and Clean Beauty


29



markets. We partner with our customers to create sustainable, high performing, low-cost molecules that replace an ingredient in their supply chains. We commercially scale and manufacture those molecules. Our revenue is generated from research and development collaboration programs, grants, renewable product sales, and license and royalty revenues from our renewable product portfolios.

All of our non-government partnerships include commercial terms for the supply of molecules we produce at commercial scale. The first molecule to generate revenue for us outside of farnesene was a fragrance molecule launched in 2015. Since the launch, this and additional fragrance molecules have continued to generate sales year over year. Our partners for these molecules are indicating continued strong growth due to their cost advantaged position, high purity of our molecules and our sustainable production method. In 2019, we commercially produced and shipped our Reb M product that is an alternative sweetener and sugar replacement for food and beverages. In 2020, we added a total of six new ingredients to our portfolio. We have a pipeline that can deliver an estimated two to three new molecules each year over the coming years.

Our time to market for molecules has decreased from seven years to less than a year for our most recent molecule, mainly due to our ability to leverage our biotechnology platform with proprietary computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. Our state-of-the-art infrastructure includes industry-leading strain engineering and lab automation located in Emeryville, California, pilot-scale production facilities in Emeryville, California and Campinas, Brazil, and a commercial-scale production facility in Leland, North Carolina (owned and operated by our Aprinnova joint venture). We are able to use a wide variety of feedstocks for production but have focused on sourcing Brazilian sugarcane for our large-scale production because of its renewability, low cost and relative price stability. We are constructing a new purpose-built, large-scale specialty ingredients facility in Brazil, which we anticipate will allow for the manufacture of up to five products concurrently, including both our specialty ingredients portfolio and our alternative sweetener product. In September 2019, we obtained the necessary permits and broke ground for this facility and we expect construction to be completed by the end of 2021. During construction, we continue to manufacture our products at manufacturing sites in Brazil, the U.S. and Europe.

Sales and Revenue

We recognize revenue from consumer and ingredient product sales, license fees and royalties, and grants and collaborations.

We have research and development collaboration arrangements for which we receive payments from our collaboration partners, which include DARPA, Koninklijke DSM N.V. (DSM), Firmenich SA (Firmenich), Givaudan International SA (Givaudan), Yifan Pharmaceutical Co. Ltd. (Yifan) and others. Some of our collaboration arrangements provide for advance payments to us in consideration for grants of exclusivity or research efforts that we will perform. Our collaboration agreements, which may require us to achieve milestones prior to receiving payments, are expected to contribute revenues from product sales and royalties if and when they are commercialized. See Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K for additional information.

We have several other collaboration molecules in our development pipeline with partners including DSM, Givaudan, Firmenich and Yifan that we expect will contribute revenues from product sales and royalties if and when they are commercialized.

COVID-19 Business Update

We have been closely monitoring the impact of the global COVID-19 pandemic on all aspects of our business, including how it has and will impact our employees, partners, supply chain, and distribution network. Before the start of the pandemic in early 2020, we developed a comprehensive response strategy including establishing a cross-functional COVID-19 task force and implementing business continuity plans to manage the impact of the COVID-19 pandemic on our employees and our business. As the pandemic has progressed, we have applied recommended public health recommendations designed to prevent the spread of COVID-19 and have been focused on the health and welfare of our employees. These recommendations to mitigate the spread of COVID-19 infection across our businesses have included additional sanitation and cleaning procedures in our laboratories and other facilities, on-site COVID-19 testing, temperature and symptom confirmations, instituting remote working when possible, and implementing social distancing and staggered worktime requirements for our employees who must work on-site. Throughout this period, we have successfully managed to sustain ongoing critical production campaigns and infrastructure while keeping our employee population healthy with no evidence of disease transmission within our onsite operations. See “Risk Factors – Business and Operational Risks - The COVID-19 pandemic has impacted our business and


30



results of operations and could have a material adverse effect on our business, results of operations and financial condition in the future” in Part I, Item 1A of our 2020 Form 10-K.

Critical Accounting Policies and Estimates

Management's discussion and analysis of results of operations and financial condition are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). We believe that the critical accounting policies described in this section are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates.

Our most critical accounting estimates include:
Recognition of revenue including arrangements with multiple performance obligations;
Valuation and allocation of fair value to various elements of complex related party transactions;
The valuation of freestanding and embedded derivatives, which impacts gains or losses on such derivatives, the carrying value of debt, interest expense and deemed dividends; and
The valuation of debt for which we have elected fair value accounting.

For a more detailed discussion of our critical accounting estimates and policies, see Note 1, "Basis of Presentation and Summary of Significant Accounting Policies" in Part II, Item 8 of our 2020 Form 10-K.

Results of Operations

Revenue
Three Months Ended March 31,
(In thousands) 2021 2020
Revenue
Renewable products $ 28,179  $ 17,854 
Licenses and royalties 143,800  5,161 
Grants and collaborations 4,880  6,115 
Total revenue $ 176,859  $ 29,130 

Total revenue increased by 507% to $176.9 million for the three months ended March 31, 2021 compared to the same period in 2020. The increase was the primarily the result of $143.6 million of license revenue from the sale of flavor and fragrance (F&F) intellectual property licenses and the assignment of certain F&F supply agreements to DSM during the three months ended March 31, 2021 (see Note 9, "Revenue Recognition"), combined with a $10.3 million increase in renewable products revenue.

Renewable products revenue increased by 58% to $28.2 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily driven by increased sales in our consumer product lines.

Licenses and royalties revenue increased by $138.6 million for the three months ended March 31, 2021 compared to the same period in 2020, due to the sale of flavor and fragrance (F&F) intellectual property licenses and the assignment of certain F&F supply agreements to DSM, as described in Note 9, "Revenue Recognition".

Grants and collaborations revenue decreased by 20% to $4.9 million for the three months ended March 31, 2021 compared to the same period in 2020, related to decreases from our customers DSM and Yifan.


31




Costs and Operating Expenses
Three Months Ended March 31,
(In thousands) 2021 2020
Cost and operating expenses
Cost of products sold $ 22,659  $ 11,790 
Research and development 23,332  17,126 
Sales, general and administrative 37,922  32,014 
Total cost and operating expenses $ 83,913  $ 60,930 

Cost of Products Sold

Cost of products sold includes the costs of raw materials, labor and overhead, amounts paid to contract manufacturers, inventory write-downs resulting from applying lower of cost or net realizable value inventory adjustments, and costs related to production scale-up. Because of our product mix, our cost of products sold does not change proportionately with changes in renewable product revenue.

Cost of products sold increased by 92% to $22.7 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to a 58% increase in total product revenue and $3.6 million of incremental costs related to raw materials price variances, inventory rework costs and manufacturing capacity fee adjustments related to our RebM ingredients product.

Research and Development Expenses

Research and development expenses increased by 36% to $23.3 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to increases in outside services related to our new squalane adjuvant project, and employee compensation.

Sales, General and Administrative Expenses

Sales, general and administrative expenses increased by 18% to $37.9 million for the three months ended March 31, 2021 compared to the same period in 2020, primarily due to increases in selling, marketing and employee compensation costs related to our consumer product lines.

Other Expense, Net
Three Months Ended March 31,
(In thousands) 2021 2020
Other income (expense):
Interest expense (5,813) (15,002)
(Loss) gain from change in fair value of derivative instruments (22,745) 3,282 
Loss from change in fair value of debt (326,785) (16,503)
Loss upon extinguishment of debt (27,313) (27,319)
Other (expense) income, net (678)
Total other expense, net $ (383,334) $ (55,538)

Total other expense, net was $383.3 million in 2021, compared to total other expense of $55.5 million in 2020. The $327.8 million change was primarily comprised of a $310.3 million increase in loss from change in fair value of debt and a $26.0 million change from a gain to a loss in change in fair value of derivative instruments, partly offset by a $9.2 million decrease in interest expense.

The increase in loss from change in fair value of debt was primarily due to a significant increase (209%) in our stock price relative to a $3.00 and $3.50 conversion price of the two debt instruments measured under the fair value option during the three months ended March 31, 2021.



32



The change from a gain to a loss in change in fair value of derivative instruments was primarily due to a significant increase (209%) in our stock price relative to the $2.87 exercise price of the mark to market liability warrants during the three months ended March 31, 2021. See Note 3, "Fair Value Measurement" in Part II, Item 8 of this Quarterly Report on Form 10-Q for details regarding our outstanding derivative instruments.

The decrease in interest expense was primarily due to a 33% decrease in total debt principal owed at March 31, 2021 in comparison to March 31, 2020, and a significant decrease in debt discount accretion.

Provision for Income Taxes

For the three months ended March 31, 2021 and 2020, we recorded provisions of $0.1 million and $0.1 million for income taxes related to accrued interest on uncertain tax positions.

Liquidity and Capital Resources
(In thousands) March 31,
2021
December 31,
2020
Working capital (working capital deficit) $ 105,115  $ (16,489)
Cash and cash equivalents $ 143,821  $ 30,152 
Debt and lease obligations $ 500,441  $ 282,187 
Accumulated deficit $ (2,377,943) $ (2,086,692)

Three Months Ended March 31,
(In thousands) 2021 2020
Net cash (used in) provided by:
Operating activities $ 108,651  $ (46,375)
Investing activities $ (2,493) $ (1,040)
Financing activities $ 7,529  $ 49,663 

Liquidity

Prior to the three months ended March 31, 2021, we have incurred operating losses since our inception, and we expect to incur losses and negative cash flows from operations through at least the next 12 months following the issuance of this Quarterly Report on Form 10-Q. As of March 31, 2021, we had working capital of $105.1 million, an accumulated deficit of $2.4 billion, and cash and cash equivalents of $143.8 million.

As of March 31, 2021, the principal amounts due under our debt instruments (including related party debt) totaled $114.7 million, of which $11.3 million is classified as current. Our debt agreements contain various covenants, including certain restrictions on our business — including restrictions on additional indebtedness, material adverse effect and cross default provisions — that could cause us to be at risk of default. A failure to comply with the covenants and other provisions of our debt instruments, including any failure to make payments when required, would generally result in events of default under such instruments, which could result in the acceleration of a substantial portion of such indebtedness. Acceleration would generally also constitute an event of default under our other outstanding debt instruments, which could result in the acceleration of a substantial portion of our debt repayment obligations.

Based on our cash and cash equivalents of $143.8 million as of March 31, 2021, plus $130.7 million of net proceeds from our April 2021 public stock offering, which together total $274.5 million, we believe that we have sufficient resources to fund our operations and capital expenditures for at least the next 12 months.

For details of our debt and equity, see the following Notes in Part I, Item 1 of this Quarterly Report on Form 10-Q:
Note 4, "Debt"
Note 5, "Mezzanine Equity"
Note 6, "Stockholders' Deficit"
Note 12. "Subsequent Events"



33



Cash Flows during the Three Months Ended March 31, 2021 and 2020

Cash Flows from Operating Activities

Our primary uses of cash from operating activities are costs related to the production and sale of our products and personnel-related expenditures, offset by cash received from renewable product sales, licenses and royalties, and grants and collaborations.

For the three months ended March 31, 2021, net cash provided by operating activities was $108.7 million, consisting primarily of a $290.1 million net loss, partially offset by $384.7 million of favorable non-cash adjustments that were primarily comprised of a $326.8 million loss from change in fair value of debt, a $27.3 million loss upon extinguishment of debt and a $22.7 million loss from change in fair value of derivative instruments. Additionally, there was a $14.0 million decrease in working capital.

For the three months ended March 31, 2020, net cash used in operating activities was $46.4 million, consisting primarily of an $87.8 million net loss, partially offset by $48.1 million of favorable non-cash adjustments that were primarily comprised of a $27.3 million loss upon extinguishment of debt, a $16.5 million loss from change in fair value of debt and $3.5 million of stock-based compensation. Additionally, there was a $6.6 million net increase in working capital balances.

Cash Flows from Investing Activities

For the three months ended March 31, 2021 and 2020, net cash used in investing activities was $2.5 million and $1.0 million, respectively, comprised of property, plant and equipment purchases.

Cash Flows from Financing Activities

For the three months ended March 31, 2021, net cash provided by financing activities was $7.5 million, primarily comprised of $32.2 million of proceeds from the exercise of warrants, partly offset by $23.2 million of debt principal payments and $2.5 million of issuance costs incurred in connection with a debt modification.
    
For the three months ended March 31, 2020, net cash provided by financing activities was $49.7 million, primarily comprised of $57.3 million of net proceeds from common stock issuances and deemed issuance, partly offset by $7.0 million of debt principal payments.

Off-Balance Sheet Arrangements

At March 31, 2021, we did not have any material off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

Contractual Obligations

The following is a summary of our contractual obligations as of March 31, 2021:

Payable by year ending December 31,
(In thousands)
Total 2021 2022 2023 2024 2025 Thereafter
Principal payments on debt $ 114,720  $ 11,231  $ 101,235  $ 293  $ 307  $ 321  $ 1,333 
Interest payments on debt
19,403  5,001  13,989  106  91  76  140 
Construction costs in connection with new production facility 23,107  23,107  —  —  —  —  — 
Marketing services commitments 19,213  4,713  3,500  3,500  3,500  4,000  — 
Equity-method investment purchase obligation 10,800  —  10,800  —  —  —  — 
Contract termination fees 5,311  5,311  —  —  —  —  — 
Financing leases 3,491  3,491  —  —  —  —  — 
Operating leases 16,769  5,644  7,655  3,320  150  —  — 
Partnership payment obligation 11,066  658  10,408  —  —  —  — 
Total $ 223,880  $ 59,156  $ 147,587  $ 7,219  $ 4,048  $ 4,397  $ 1,473 



34



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The market risk inherent in our market risk sensitive instruments and positions is the potential loss arising from adverse changes in the price of our common stock, foreign currency exchange rates, interest rates and commodity prices.

Amyris Common Stock Price Risk

We are exposed to potential losses related to the price of our common stock. At each balance sheet date, the fair value of our derivative liabilities and certain of our outstanding debt instruments for which we have elected fair value accounting, is remeasured using current fair value inputs, one of which is the price of our common stock.

During any particular period, if the price of our common stock increases, there will likely be increases in the fair value of our derivative liabilities and our debt instruments for which we have elected fair value accounting. Such increases in fair value will result in losses in our condensed consolidated statements of operations from change in fair value of derivative instruments and from change in fair value of debt. Conversely, a decrease in the price of our stock during any particular period will likely result in gains in relation to these derivative and debt instruments. Given the current and historical volatility of our common stock price, any changes period-over-period have and could in the future result in a significant change in the fair value of our derivative liabilities and convertible debt instruments and significantly impact our net income during the period of change.

Foreign Currency Exchange Risk

Most of our sales contracts are denominated in U.S. dollars, and therefore our revenues are not currently subject to significant foreign currency risk.
The functional currency of our consolidated Brazilian subsidiary is the local currency (Brazilian Real), in which recurring business transactions occur. We do not use currency exchange contracts as hedges against our investment in that subsidiary.
Our permanent investment in Brazil was $22.0 million as of March 31, 2021 and $18.5 million as of December 31, 2020, using the exchange rate at each date. A hypothetical 10% adverse change in Brazilian Real exchange rates would have had an adverse impact to Other Comprehensive Loss of $2.2 million as of March 31, 2021 and $1.9 million as of December 31, 2020.
We have also evaluated foreign currency exposure in relation to our other non-U.S. Dollar denominated assets and liabilities and determined that there would be an immaterial effect on our results of operations from 10% exchange rate fluctuations between those currencies and the U.S. Dollar.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our outstanding debt obligations, including embedded derivatives therein. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of March 31, 2021, our investment portfolio consisted of money market funds and certificates of deposit, both of which are highly liquid. Due to the short-term nature of our investment portfolio, we do not believe that an immediate 10% increase in interest rates would have a material effect on the fair value of our portfolio. Since we believe we have the ability to liquidate our investment portfolio, we expect that our operating results or cash flows would not be materially affected by a sudden change in market interest rates on the portfolio.

In addition, while not likely in the current and significantly extended low interest rate environment, changes in interest rates could significantly change the fair value of our embedded derivative liabilities.
    
As of March 31, 2021, all of our outstanding debt is in fixed rate instruments. As a result, changes in interest rates would not affect interest expense and payments in relation to our debt.

Commodity Price Risk
Our primary exposure to market risk for changes in commodity prices relates to our procurement of products from contract manufacturers and other suppliers whose prices are affected by the price of sugar feedstocks. Our suppliers manage exposure to this risk primarily through the use of feedstock pricing agreements.



35




ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of March 31, 2021, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

There were no changes in our internal control over financial reporting identified in management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.


36



PART II
ITEM 1. LEGAL PROCEEDINGS

For a description of our significant pending legal proceedings, please see Note 8, "Commitments and Contingencies" in the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.




37



ITEM 1A. RISK FACTORS

The risks described in Part I, Item 1A, "Risk Factors" in our 2020 Form 10-K could materially and adversely affect our business, financial condition and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face; our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. The “Risk Factors” section of the 2020 Form 10-K remains current in all material respects.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Item 8.01 Other Events

On May 7, 2021, the Company entered into a Securities Purchase Agreement (the Upland SPA) with Upland1, LLC (Upland) and the members of Upland (the Upland Selling Stockholders). Subject to the terms and conditions of the Upland SPA, the Company has agreed to acquire the outstanding membership units of Upland from the Upland Selling Stockholders and to settle and pay off certain convertible promissory notes of Upland held by certain holders (the Specified Upland Noteholders), for an aggregate consideration that consists of a payment of cash consideration and issuance by the Company of shares of the Company’s common stock representing, collectively, less than 1% of the Company’s outstanding shares (the Unregistered Securities) to certain Upland Selling Stockholders and Specified Upland Noteholders.

Furthermore, pursuant to the terms and conditions of the Upland SPA, the Company agreed to file a Prospectus Supplement, which supplements the Prospectus filed with the Securities and Exchange Commission on April 7, 2021 together with a Registration Statement on Form S-3, to register the resale of the Unregistered Securities (the Upland Offering). Each of the Upland Selling Stockholders and the Upland Noteholders will sell its respective Unregistered Securities. The Company will not receive any proceeds from the Upland Offering. A copy of the opinion of Fenwick & West LLP, relating to the validity of certain of the shares in connection with the Upland Offering, is filed as exhibit 5.1 to this Quarterly Report on Form 10-Q.


38



ITEM 6. EXHIBITS
Exhibit No. Description Incorporation by Reference
Form File No. Exhibit Filing Date Filed Herewith
4.01 S-3ASR 333-255105 4.18 04.07.2021
4.02 x
4.03 x
5.01 x
10.01a
x
10.02 x
23.01 x
31.01 x
31.02 x
32.01b
x
32.02b
x
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

a Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated under the Exchange Act.
b
This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.



39



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

AMYRIS, INC.
By:
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer
(Principal Executive Officer)
May 7, 2021
By:
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer
(Principal Financial Officer)
May 7, 2021



40

Exhibit 4.02
AMENDMENT TO NOTES
March 1, 2021
PARTIES:        Amyris, Inc., a Delaware corporation (“Borrower”)
DSM Finance B.V., a Netherlands private company with limited liability (“Lender”)
RECITALS
A.Borrower has issued to Lender a promissory note, dated as of December 28, 2017 (as amended, supplemented or modified from time to time, the “2017 Note”), in the aggregate principal amount of $25,000,000.00 pursuant to that certain Credit Agreement, dated as December 28, 2017 (as amended, supplemented or modified from time to time, the “2017 Credit Agreement”), by and between Borrower and Lender.
B.Borrower has issued to Lender (i) a secured promissory note, dated as of September 17, 2019 (as amended, supplemented or modified from time to time, the “First 2019 Note”), in the aggregate principal amount of $3,000,000.00, (ii) a secured promissory note, dated as of September 19, 2019 (as amended, supplemented or modified from time to time, the “Second 2019 Note”), in the aggregate principal amount of $3,000,000.00, and (iii) a secured promissory note, dated as of September 23, 2019 (as amended, supplemented or modified from time to time, the “Third 2019 Note” and, together with the First 2019 Note and the Second 2019 Note, the “2019 Notes”; the 2019 Notes, together with the 2017 Note, the “Notes”), in the aggregate principal amount of $2,000,000.00, in each case pursuant to that certain Credit Agreement, dated as September 17, 2019 (as amended, supplemented or modified from time to time, the “2019 Credit Agreement” and, together with the 2017 Credit Agreement, the “Credit Agreements”; the Credit Agreements, together with the Notes and the other Loan Documents (as defined in the 2019 Credit Agreement), the “Note Documents”), by and between Borrower and Lender.
C.Borrower has requested that an affiliate of Lender, and in connection with this amendment (this “Amendment”) such affiliate has agreed, to waive certain obligations arising under agreements between Borrower and such affiliate.
D.Borrower and Lender have agreed, subject to terms and conditions contained in this Amendment, to amend the Notes.
AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower and Lender agree as follows:
SECTION 1.Amendments to Notes. Subject to Section 3:
1.1    Amendments to 2017 Note.
1.1.1. The first paragraph of the 2017 Note is hereby amended by adding after the words “2.5% per quarter” the following words: “(or, from and after April 1, 2021 until December 31, 2021, solely to the extent that Company has not, prior to April 1, 2021, (i) repaid all Obligations under this Note, together with all accrued and unpaid interest and the Prepayment Fee in connection herewith, and (ii) repaid all Obligations (as defined in the 2019 Notes) outstanding under the 2019 Notes (including, without limitation, all accrued and unpaid interest and the Prepayment Fee in connection therewith) in full in cash, 5.85% per quarter (which such

|US-DOCS\121184127.7||


incremental interest of 3.35% (the “Incremental Interest”) represents the Prepayment Fee, to be paid over the nine-month period from April 1, 2021 to December 31, 2021)”.
1.1.2. Section 1 of the 2017 Note is hereby amended by adding the following proviso at the end thereof:
; provided that (i) if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption and (ii) if the Prepayment Fee has not been paid pursuant to a redemption of this Note on or before March 31, 2021 and Borrower redeems this Note (or this Note is accelerated for any reason), in whole or in part, between April 1, 2021 and December 31, 2021, Borrower shall be required to pay to Lender a redemption fee equal to the Prepayment Fee (a) minus any Incremental Interest that Borrower has paid to Lender after April 1, 2021 through the date of such redemption (b) plus 4.00% per quarter on the Prepayment Fee, pro rata based on the number of days elapsed from April 1, 2021 through the date of such redemption (which such redemption shall occur no later than December 31, 2021).
1.1.3. Section 4 of the 2017 Note is hereby amended by adding the following defined terms in appropriate alphabetical order:
2019 Notes” has the meaning assigned to such term in the First Amendment.
First Amendment” means the Amendment to Notes, dated as of February 23, 2021, by and between Borrower and Lender.
Prepayment Fee” has the meaning assigned to such term in the First Amendment.
1.1.4. The 2017 Note is hereby amended by adding the following Section 6 immediately following Section 5 thereof:
6. Prepayment Fee.    Section 4 of the First Amendment is hereby incorporated herein by reference and made a part of this Note as if set forth herein in full.
1.1.5. The 2017 Note is hereby amended by adding the following Section 7 immediately following Section 6 thereof:
7. Interest Rate Limitation.     Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to this Note, together with all fees, charges and other amounts which are treated as interest on this Note under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender in accordance with applicable law, the rate of interest payable in respect of this Note hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of this Note but were not payable as a result of the operation of this Section 7 shall be cumulated and the interest and Charges payable to the Lender in respect of other Obligations or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon to the date of repayment, shall have been received by the Lender.

2


1.2. Amendments to 2019 Notes.
1.2.1. Section 4 of each 2019 Note is hereby amended by adding the following defined term in appropriate alphabetical order:
First Amendment” means the Amendment to Notes, dated as of February 23, 2021, by and between Borrower and Lender.
Prepayment Fee” has the meaning assigned to such term in the First Amendment.
1.2.2. Each 2019 Note is hereby amended by adding the following Section 6 immediately following Section 5 thereof:
6. Prepayment Fee.    Section 4 of the First Amendment is hereby incorporated herein by reference and made a part of this Note as if set forth herein in full.
1.2.3. Each 2019 Note is hereby amended by adding the following Section 7 immediately following Section 6 thereof:
7. Interest Rate Limitation.     Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to this Note, together with all fees, charges and other amounts which are treated as interest on this Note under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender in accordance with applicable law, the rate of interest payable in respect of this Note hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of this Note but were not payable as a result of the operation of this Section 7 shall be cumulated and the interest and Charges payable to the Lender in respect of other Obligations or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon to the date of repayment, shall have been received by the Lender.
1.2.4. Section 1(a) of the First 2019 Note is hereby amended by adding the following proviso at the end thereof:
; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.2.5. Section 1(a) of the Second 2019 Note is hereby amended by adding the following proviso at the end thereof:
; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.2.6    Section 1(a) of the Third 2019 Note is hereby amended by adding the following proviso at the end thereof:
3


; provided that, if any redemption of this Note, in whole or in part, shall occur on or before March 31, 2021, the Prepayment Fee shall be due and payable in connection with, and on the same date as, the first such redemption.
1.3.    The “Prepayment Fee” shall mean $2,500,000 in the aggregate for all redemptions, in whole or in part, during the period from the date of this Amendment through and including March 31, 2021 (or, solely with respect to clause (ii) of the proviso in Section 1 of the 2017 Note after giving effect to the Amendment, during the period from April 1, 2021 to December 31, 2021), of the 2017 Note and/or any 2019 Note.
SECTION 2.Representations and Warranties; Ratification.
2.1.    Borrower represents and warrants to Lender:
2.1.1.    The execution, delivery and performance by Borrower of this Amendment and the consummation by Borrower of the transactions contemplated hereby (i) are within the corporate power of Borrower and (ii) have been duly authorized by all necessary corporate actions on the part of Borrower.
2.1.2.    This Amendment has been duly executed and delivered by Borrower and constitutes a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.
2.1.3.    The execution and delivery by Borrower of this Amendment and the performance and consummation by Borrower of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of Borrower or any judgment, order, writ, decree, statute, rule or regulation applicable to Borrower; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any mortgage, indenture, agreement, instrument or contract to which Borrower is a party or by which it is bound except to the extent such violation, breach or acceleration could not reasonably be expected to result in a Material Adverse Effect (as defined in each Credit Agreement); or (iii) other than Liens (as defined in each Credit Agreement) securing the Obligations (as defined in each Credit Agreement), result in the creation or imposition of any Lien upon any property, asset or revenue of Borrower or the suspension, revocation, impairment, forfeiture, or nonrenewal of any permit, license, authorization or approval applicable to Borrower, its business or operations, or any of its assets or properties except to the extent such suspension, revocation, impairment, forfeiture or nonrenewal could not reasonably be expected to have a Material Adverse Effect.
2.1.4. As of the date hereof, no Event of Default (as defined in each applicable Note Document) shall have occurred and be continuing.
2.2. Borrower reaffirms the terms and conditions of each Note Document and acknowledges and agrees that each and every such Note Document remains in full force and effect and is hereby reaffirmed, ratified and confirmed.
SECTION 3.Conditions. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent:
3.1. This Amendment shall have been executed by Borrower and Lender, and counterparts hereof as executed by Borrower (which may include electronic transmission of a signed signature page) shall have been delivered to Lender.
3.2. The representations and warranties made by Borrower in Section 2 of each Credit Agreement shall be true and correct as of the date hereof.
4



SECTION 4.
4.1. Notwithstanding anything to the contrary in this Amendment or any other Note Document, Borrower and Lender hereby acknowledge and agree that, if any of the Obligations (as defined in each Credit Agreement) are accelerated as a result of the occurrence and continuance of any Event of Default (as defined in each applicable Note Document) on or prior to December 31, 2021 (all such accelerated Obligations, the “Accelerated Obligations”) (including but not limited to (i) by operation of law or otherwise, (ii) acceleration in accordance with the terms of the Note Documents, (iii) the satisfaction, release, payment, restructuring, reorganization, replacement, reinstatement, defeasance or compromise of any of the Obligations (as defined in each Credit Agreement) in any voluntary or involuntary case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent or other similar event in respect of Borrower described in Section 3(a)(v) of the 2017 Note or Section 3(a)(iv) of the 2019 Notes, (iv) the making of a distribution of any kind in any proceeding under the Title 11 of the United States Code, as amended (U.S. Bankruptcy Code) to Lender in full or partial satisfaction of the Obligations (as defined in each Credit Agreement) or (v) the termination of this Note Documents for any reason), the Prepayment Fee in respect of the Accelerated Obligations will also be due and payable on the date of such acceleration and will be treated and deemed as though the Notes were prepaid as of such date and shall constitute part of the Obligations (as defined in each Credit Agreement) for all purposes herein, in view of the impracticability and extreme difficulty of ascertaining actual damages and by mutual agreement of the parties as to a reasonable calculation of Lender’s lost profits as a result thereof. BORROWER EXPRESSLY WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE PREPAYMENT FEE IN CONNECTION WITH ANY SUCH ACCELERATION. Further, (i) Borrower and Lender expressly agree that the Prepayment Fee is reasonable and is the product of an arm’s length transaction between sophisticated business people, ably represented by counsel, and (ii) Borrower expressly agrees that (1) the Prepayment Fee shall be payable notwithstanding the then prevailing market rates at the time payment is made, (2) there has been a course of conduct between Lender and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Fee, (3) Borrower shall be estopped hereafter from claiming differently than as agreed to in this Section 4.1 and (4) Borrower’s agreement to pay the Prepayment Fee is a material inducement to Lender to continue to hold the Notes.
SECTION 5.Miscellaneous.
5.1. This Amendment shall be a Note Document. All references to any Note Document shall be a reference to such Note Document as so amended by this Amendment.
5.2. This Amendment and the other Note Documents (as amended by this Amendment) constitute the full and entire understanding and agreement between the parties relating to the subject matter hereof and thereof and supersede any previous written or verbal agreements between the parties with regard to the subject matter hereof and thereof.
5.3. Notwithstanding any provision contained herein, nothing contained herein shall limit any rights or remedies under the Note Documents or applicable law based on any breaches, failures, defaults or Events of Default (as defined in each applicable Note Document) thereunder.
5.4. This Amendment and all actions arising out of or in connection with this Amendment shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the State of New York.
5


5.5. The rights and obligations of Borrower and Lender hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and transferees of the parties
5.6. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument.
5.7. If any provision of this Amendment shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
[Signature Pages Follow]

6


IN WITNESS WHEREOF, this Amendment is executed and delivered as of the day and year first above written.
Borrower:                    Amyris, Inc., a Delaware corporation

By: /s/ John Melo
Name: John Melo
Title: President and Chief Executive Officer

Lender:    DSM Finance B.V., a Netherlands private company with limited liability

By: /s/ B. Singh
Name: B. Singh
Title: Managing Director

By: /s/ L. Huang
Name: L. Huang
Title: Managing Director
[Signature Page – Amendment to Notes]
Exhibit 4.03

EXECUTION VERSION
AMENDMENT TO NOTE
March 31, 2021
PARTIES:     Amyris, Inc., a Delaware corporation (“Borrower”)
DSM Finance B.V., a Netherlands private company with limited liability (“Lender”)
RECITALS
A. Borrower has issued to Lender a promissory note, dated as of December 28, 2017 (as amended, supplemented or modified from time to time, the “Note”), in the aggregate principal amount of $25,000,000.00 pursuant to that certain Credit Agreement, dated as December 28, 2017 (as amended, supplemented or modified from time to time, the “Credit Agreement” and, together with the Note, the “Note Documents”), by and between Borrower and Lender.
B. As of the date of this Amendment, Borrower has made (i) a partial prepayment of the Note of $15,000,000.00 of principal and (ii) a payment of the Prepayment Fee in the amount of $2,500,000.00 pursuant to the terms of the Note, which such payments have resulted in the remaining outstanding principal amount of $10,000,000.00 under the Note.
C. Borrower has requested that an affiliate of Lender, and in connection with this amendment (this “Amendment”) such affiliate has agreed, to waive certain obligations arising under agreements between Borrower and such affiliate.
D. Borrower and Lender have agreed, subject to terms and conditions contained in this Amendment, to amend the Note.

AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower and Lender agree as follows:
SECTION 1. Amendments to Note. Subject to Section 3:
1.1. The first paragraph of the Note is hereby amended by replacing the words “no later than December 31, 2021” therein with the words “no later than April 15, 2022”.
1.2. Notwithstanding anything to the contrary in the Note, the interest rate to be paid on the outstanding principal of the Note as of the date of this Amendment until final maturity shall be 2.5% per quarter.
SECTION 2. Representations and Warranties; Ratification.
2.1. Borrower represents and warrants to Lender:
2.1.1. The execution, delivery and performance by Borrower of this Amendment and the consummation by Borrower of the transactions contemplated hereby (i) are within the corporate power of Borrower and (ii) have been duly authorized by all necessary corporate actions on the part of Borrower.
2.1.2. This Amendment has been duly executed and delivered by Borrower and



constitutes a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.
2.1.3. The execution and delivery by Borrower of this Amendment and the performance and consummation by Borrower of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of Borrower or any judgment, order, writ, decree, statute, rule or regulation applicable to Borrower; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any mortgage, indenture, agreement, instrument or contract to which Borrower is a party or by which it is bound except to the extent such violation, breach or acceleration could not reasonably be expected to result in a Material Adverse Effect (as defined in the Credit Agreement); or (iii) other than Liens (as defined in the Credit Agreement) securing the Obligations (as defined in the Credit Agreement), result in the creation or imposition of any Lien upon any property, asset or revenue of Borrower or the suspension, revocation, impairment, forfeiture, or nonrenewal of any permit, license, authorization or approval applicable to Borrower, its business or operations, or any of its assets or properties except to the extent such suspension, revocation, impairment, forfeiture or nonrenewal could not reasonably be expected to have a Material Adverse Effect.
2.1.4. As of the date hereof, no Event of Default (as defined in each applicable Note Document) shall have occurred and be continuing.
2.2. Borrower reaffirms the terms and conditions of each Note Document and acknowledges and agrees that each and every such Note Document remains in full force and effect and is hereby reaffirmed, ratified and confirmed.
SECTION 3. Conditions. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent:
3.1. This Amendment shall have been executed by Borrower and Lender, and counterparts hereof as executed by Borrower (which may include electronic transmission of a signed signature page) shall have been delivered to Lender.

3.2. The representations and warranties made by Borrower in Section 2 of the Credit Agreement shall be true and correct as of the date hereof.
SECTION 4. [Reserved].
SECTION 5. Miscellaneous.
5.1. This Amendment shall be a Note Document. All references to any Note Document shall be a reference to such Note Document as so amended by this Amendment.
5.2. This Amendment and the other Note Documents (as amended by this Amendment) constitute the full and entire understanding and agreement between the parties relating to the subject matter hereof and thereof and supersede any previous written or verbal agreements between the parties with regard to the subject matter hereof and thereof.
5.3. Notwithstanding any provision contained herein, nothing contained herein shall limit any rights or remedies under the Note Documents or applicable law based on any breaches, failures, defaults or
2




Events of Default (as defined in each applicable Note Document) thereunder.
5.4. This Amendment and all actions arising out of or in connection with this Amendment shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the State of New York.
5.5. The rights and obligations of Borrower and Lender hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and transferees of the parties
5.6. This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument.
5.7. If any provision of this Amendment shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
[Signature Pages Follow]
3




IN WITNESS WHEREOF, this Amendment is executed and delivered as of the day and year first above written.
Borrower:                    Amyris, Inc., a Delaware corporation

By: /s/ Han Kieftenbeld
Name: Han Kieftenbeld
Title: Chief Financial Officer

Lender:    DSM Finance B.V., a Netherlands private company with limited liability

By: /s/ Vivian Huang
Name: Vivian Huang
Title: Corporate Finance Manager

By: /s/ Brune Singh
Name: Brune Singh
Title: Vice President Group Treasury



Exhibit 5.01


IMAGE_03.JPG
May 7, 2021
Amyris, Inc.
5885 Hollis Street, Ste. 100
Emeryville, California 94608
Ladies and Gentlemen:
We deliver this opinion with respect to certain matters in connection with the offering by the Selling Stockholders (as defined below) of 98,352 shares of the common stock of Amyris, Inc., a Delaware corporation (the “Company”), par value $0.0001 per share (the “Shares”), issued to the Selling Stockholders (as defined below) pursuant to that certain Securities Purchase Agreement, dated as of May 7, 2021 (the “Purchase Agreement”), by and among the Company, Upland1, LLC (“Upland”), Francisco Costa, Michele Levy and other Upland’s securityholders listed on Schedule II thereto, and to certain noteholders of the Company (the “Selling Stockholders”). The Shares are registered and offered pursuant to an automatic shelf Registration Statement on Form S-3 (File No. 333-255105) filed by the Company with the Securities and Exchange Commission (the “Commission”) on April 7, 2021 (the “Registration Statement”), in connection with the registration under the Securities Act of 1933, as amended (the “Securities Act”) the prospectus filed therewith (the “Base Prospectus”) and the prospectus supplement dated May 7, 2021 (the “Prospectus Supplement”) filed with the Commission pursuant to Rule 424(b) under the Securities Act (The Base Prospectus and the Prospectus Supplement are collectively referred to as the “Prospectus”). The Shares may be sold from time to time by the Selling Stockholders, as set forth in the Registration Statement and the Prospectus. The offering of the Shares by the Selling Stockholders pursuant to the Registration Statement and the Prospectus is referred to herein as the “Offering.”
In connection with our opinion expressed below we have examined originals or copies of the Purchase Agreement, the Registration Statement, the Company’s Restated Certificate of Incorporation, as amended (the “Restated Certificate”) and the Company’s Restated Bylaws, as amended (the “Bylaws” and, together with the Restated Certificate, as each may be amended, modified or restated, the “Charter Documents”), certain minutes and consents of the Company’s board of directors (the “Board”) or a committee or committees thereof relating to the Registration Statement, the Charter Documents, the Purchase Agreement, the Offering, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we have also relied upon a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations.
In our examination of documents we have assumed, and express no opinion as to, the genuineness of all signatures on documents submitted to us, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the absence of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof.




Amyris, Inc.
Page 2
May 7, 2021

We render this opinion only with respect to, and express no opinion herein concerning the application or effect of any laws other than the existing laws of the Delaware General Corporation Law.
In connection with our opinions expressed below, we have assumed that, (i) at or prior to the time of the issuance and delivery of any of the Shares by the Company to the Selling Stockholders and as of the date hereof, there will not have occurred any change in the law or the facts affecting the validity of the Shares, any change in actions of the Board or the Company’s stockholders, or any amendments to the Charter Documents, and (ii) at the time of the issuance and as of the date hereof, no stop order suspending the Registration Statement’s effectiveness will have been issued and remain in effect, and that the Registration Statement will not have been modified or rescinded. We also have assumed that the issuance and delivery of the Shares by the Company to the Selling Stockholders, immediately prior to the rendition of this opinion, is in compliance by the Company with the terms of the Shares and will not result in a violation of any provision of any of the Charter Documents or of any instrument or agreement then binding upon the Company or any restriction imposed by any court or governmental body then having jurisdiction over the Company.
Based upon the foregoing, we are of the following opinion: 98,352 Shares issued by the Company to the Selling Stockholders and to be sold from time to time by the Selling Stockholders, are validly issued, fully paid and nonassessable.
We consent to the use of this opinion as an exhibit to the Quarterly Report on Form 10-Q to be filed by the Company with the Commission, and further consent to all references to us, if any, in the Registration Statement, the Prospectus and any amendments or supplements thereto, as applicable. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
[Concluding Paragraph Follows on Next Page]




Amyris, Inc.
Page 3
May 7, 2021

This opinion is intended solely for use in connection with the issuance and sale of the Shares by the Selling Stockholders subject to the Registration Statement and the Prospectus and is not to be relied upon for any other purpose. In providing this opinion, we are opining only as to the specific legal issues expressly set forth above and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks, only as of the date of this letter first written above and is based solely on our understanding of facts in existence as of such date after the aforementioned examination and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.
Very truly yours,
/s/ Fenwick & West LLP
FENWICK & WEST LLP

Exhibit 10.01

IN ACCORDANCE WITH ITEM 601(b)(10)(iv) OF REGULATION S-K, CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE CONFIDENTIAL INFORMATION IS DENOTED HEREIN BY [*].


Execution Version

ASSET PURCHASE AGREEMENT
by and among
DSM Nutritional Products Ltd.,
as Buyer,
Amyris, Inc.,
as Seller,
dated as of March 31, 2021
IMAGE_01.JPG


Table of Contents
Definitions    1
Purchase and Sale of Assets    7
Assumed Liabilities    8
Excluded Assets    8
Excluded Liabilities    9
Withholding    10
Closing    11
Deliveries by Buyer    11
Deliveries by Seller    11
Further Assurances    12
Earn-Out Payments    12
Organization and Authority    16
No Conflicts; Consents    16
Consents and Approvals    17
Compliance with Law; Litigation and Claims    17
Assumed Contracts    18
Inventory    18
R&D Obligations    18
Brokers    18
No Implied Representations    19
Organization and Authority    19
No Conflicts; Consents    19
Consents and Approvals    19
Sufficient Funds    20
No Other Representations    20
IMAGE_21.JPG IMAGE_01.JPG


Table of Contents
Expenses    20
Tax Matters    20
Cooperation in Litigation Matters    22
Escrow Agreement    22
Conduct of the Business    22
Survival    22
Buyer’s Off-Set Right    24
Public Statements    24
Notices    24
Assignment    25
Entire Agreement    26
Counterparts; Effectiveness; Third Party Beneficiaries    26
Representation by Legal Counsel    27
Section Headings; Construction    27
Validity    27
Specific Performance    27
IMAGE_21.JPG IMAGE_01.JPG


Exhibits
Exhibit A — Form of Bill of Sale and Assignment and Assumption Agreement
Exhibit B — License and Drawing Rights Agreement
Exhibit C — Supply Agreement
Schedules
Schedule 1.1(a)
Schedule 2.1.2
Schedule 2.1.4
Schedule 2.1.5
Schedule 3.3
Schedule 3.5.1
Schedule 3.5.5
Assumed Contracts
Products and related Technical Transfer Packages
Accounts Receivable
Inventory
Conditions Precedent
Annual Launch Business EBITDA
Value Share Guarantee
IMAGE_21.JPG IMAGE_01.JPG


ASSET PURCHASE AGREEMENT
This ASSET PURCHASE AGREEMENT is entered into as of March 31, 2021 by and among DSM Nutritional Products, Ltd. a Switzerland limited company (“Buyer”) and Amyris, Inc., a Delaware corporation (“Seller”).
RECITALS
WHEREAS, Seller desires to sell to Buyer, and Buyer desires to acquire from Seller, the Purchased Assets (as defined herein), and Buyer desires to assume, pay, perform and discharge the Assumed Liabilities (as defined herein), all on the terms and conditions set forth in this Agreement (as defined herein).
NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements contained herein, Seller and Buyer, intending to be legally bound, hereby agree as set forth herein.
ARTICLE 1
DEFINITIONS
1.1.Definitions. For the purposes of this Agreement, capitalized terms used herein have the meaning set forth below (the singular shall be interpreted to include the plural and vice versa, unless the context clearly dictates otherwise):
2022 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
2023 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
2024 Value Share    Guarantee Amount”    has    the meaning    set    forth in Section 3.5.5.
Accounts Receivable” has the meaning set forth in Section 2.1.
Action” means any action, claim, demand, proceeding, citation, summons, subpoena, arbitration, audit, investigation, hearing, litigation or suit of any nature (whether civil, criminal, administrative or judicial, whether formal or informal, and whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Authority.
Affiliate” means, with respect to any Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For the avoidance of doubt, in no event shall Amyris or any of its Subsidiaries be deemed to be an Affiliate of Buyer or any of its direct or indirect equity holders or Subsidiaries for any purpose hereunder.
Aggregate Earn-Out Cap” has the meaning set forth in Section 3.5.1.



Agreement” means this Asset Purchase Agreement, and the Schedules and Exhibits hereto, as amended, modified or supplemented from time to time.
Annual Launch Business EBITDA” means, for each of the calendar years 2022, 2023 and 2024, the earnings before interest, taxes, depreciation and amortization for such calendar year, in each case, consisting of the accounts and items identified on Schedule 3.5.1, determined in accordance with GAAP, subject to the adjustments contemplated by Schedule 3.5.1, and in accordance with the sample calculation set forth on Schedule 3.5.1.
Arbitrating Accountant” has the meaning set forth in Section 3.5.2.
Assumed Contract” means each contract set forth on Schedule 1.1(a) hereto.
Assumed Liabilities” has the meaning set forth in Section 2.2.
Bill of Sale and Assignment and Assumption Agreement” means the Bill of Sale and Assignment and Assumption Agreement pursuant to which the Purchased Assets will be sold and transferred to, and the Assumed Liabilities will be assumed by, Buyer at the Closing, substantially in the form attached as Exhibit A hereto.
Bisabolol” means [*] and meeting the product specifications agreed by [*].
Business” means the business, operations and activities of Seller’s flavors and fragrances (F&F) business as conducted by the Seller and any of its Subsidiaries consisting of manufacturing, marketing, distribution and sale activities related to the Molecules, in each case, as conducted by Seller and its Subsidiaries prior to the Closing.
Business Books and Records” has the meaning set forth in Section 2.1.
Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York City, New York, Switzerland or the Netherlands are authorized or required by Law to close.
Business Tax Records” means all books and records relating to Taxes with respect to the Purchased Assets and the Assumed Liabilities.
Buyer” has the meaning set forth in the preamble to this Agreement.
Closing” has the meaning set forth in Section 3.1.
Closing Date” has the meaning set forth in Section 3.1.
Code” means the U.S. Internal Revenue Code of 1986, as amended.
Confidential Information” has the meaning set forth in Section 6.3.1.
Consent” means any consent, approval, authorization, consultation, waiver, permit, grant, agreement, certificate, exemption, order, registration, declaration, filing, license, notice of, with or to any Person or under any Law, in each case, required to permit the consummation of the Contemplated Transactions.



Contemplated Transactions” means the transactions contemplated by this Agreement and the other Transaction Documents.
Contract” means any loan or credit agreement, bond, debenture, note, mortgage, indenture, lease, supply agreement, license agreement, development agreement, purchase order or other contract, agreement, obligation, commitment or instrument that is legally binding, including all amendments, schedules and exhibits thereto.
Data Room” means the on-line “virtual data room” established by the Seller and/or its Representatives in connection with the Contemplated Transactions, hosted by Fenwick & West (available at: [*]).
Designated Court” has the meaning in Section 8.6.1.
Earn-Out Payment Statement of Objections” has the meaning set forth in Section 3.5.2.
Earn-Out Period” has the meaning set forth in Section 3.5.1.
Earn-Out Schedule” has the meaning set forth in Section 3.5.2.
Encumbrance” means any lien, mortgage, adverse ownership claim, attachment, levy, charge, easement, option or other right to acquire an interest, restriction, pledge, security interest, title defect, encroachment or other similar encumbrance, whether of record or not.
Enforceability Exceptions” has the meaning set forth in Section 4.1.
Escrow Agreement” means each of (i) the Strain Escrow Agreement by and between Amyris, Inc, Givaudan International, SA and SciSafe Inc. effective September 28, 2018 to be amended following Closing to include reference to Buyer (as may be amended or modified by the parties thereto), and (ii) the Escrow Agreement by and between Amyris, Inc., Firmenich SA and SciSafe Inc. effective August 22, 2013, as amended December 23, 2016 to be amended following closing to include reference to Buyer (as may be amended or modified by the parties thereto).
Excluded Assets” has the meaning set forth in Section 2.3.
Excluded Books and Records” has the meaning set forth in Section 2.3.3.
Excluded Liabilities” has the meaning set forth in Section 2.4.
Firmenich Collaboration Agreement” means the Collaboration Agreement dated as of March 13, 2013, by and between Seller and Firmenich SA as amended by Amendment 1 dated July 1, 2015, as further amended by Amendment 2 dated November 28, 2016, as further amended by Amendment 3 dated July 1, 2017, and as further amended by Amendment 5 dated December 18, 2019.
Firmenich Supply Agreement” means the Amended and Restated Supply Agreement by and between Amyris and Firmenich dated August 29, 2018.



Framework Supply Agreement” means the Framework Supply Agreement by and between Amyris and Givaudan dated January 1, 2019.
[*].
GAAP” means generally accepted accounting principles in the United States, as in effect from time to time and consistently applied.
Givaudan Collaboration Agreement” means the Collaboration Agreement dated as of September 14, 2018, by and between Seller and Givaudan International SA.
Governmental Authority” means any arbitrator, court, judicial, legislative, administrative or regulatory agency, commission, department, board, bureau or body or other government authority or instrumentality or any Person or entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, whether foreign or domestic, whether federal, national, supranational, state, provincial, municipal, local or other.
Guarantee Amount” has the meaning set forth in Section 3.5.6.
Indemnified Party” has the meaning set forth in Section 7.3.
Indemnifying Party” has the meaning set forth in Section 7.3.
Intellectual Propertyhas the meaning set forth in Section 1.21 of the License and Drawing Rights Agreement.
Knowledge of Seller” means the actual knowledge of the following officers of Seller: John Melo (Chief Executive Officer), Han Kieftenebld (Chief Financial Officer), Jim Iacoponi (SVP, Nutrition Ingredients) and Eduardo Alvarez (Chief Operating Officer) after reasonable inquiry of such Seller employees that such named individuals reasonably believe would have actual knowledge of the applicable matter.
Launch Business” means the sale of [*], Sclareol and Retinol pursuant to the applicable Assumed Contracts.
Launch Business Forecast Amount” means the forecasted sales for the Launch Business for a given year prepared by Buyer in good faith based on the budgets, forecasts or projected sales delivered to Buyer by the Launch Business customers.
Law” means, with respect to any Person, all international, national, federal, state, foreign or local statutes, laws, ordinances, regulations, rules, codes, judgments, orders or other requirements or rule of law of any Governmental Authority having jurisdiction over such Person.
Liability” or “Liabilities” means any and all debts, liabilities, commitments, guarantees and obligations, whether accrued or fixed, absolute or contingent, known or unknown, matured or unmatured, determined or determinable, and whether or not such item is required to be accrued as a liability in financial statements prepared in accordance with applicable accounting standards, including those arising under any Law or Action and those arising under any Contract.



License and Drawing Rights Agreementmeans the agreement pursuant to which (i) Seller grants Buyer an exclusive license in certain intellectual property relating to the Molecules and (ii) Buyer agrees to engage Seller to provide certain development and piloting services with respect to the Molecules, substantially in the form attached as Exhibit B hereto.
Loss” or “Losses” means losses, damages, adverse claims, Actions, obligations, demands, debts, fines, penalties, Liabilities, judgments, settlements, Taxes, costs or expenses, including costs of investigation, defense and settlement and documented attorneys’ and other professional fees and expenses.
Manool” means [*] and meeting the product specifications agreed by [*].
Molecules” means [*], Patchouli, Manool, Sandalwood, Bisabolol, [*], Sclareol and Retinol and Farnesene.
Non-Recourse Party” has the meaning set forth in Section 8.12.1.
Party” means each of Seller and Buyer, and “Parties” means Seller and Buyer.
Patchouli” means [*] and meeting the product specifications agreed by [*].
Permitted Encumbrance” means any Encumbrance for Taxes not yet due, assessed or payable.
Person” means an individual, a corporation, a limited liability company, a partnership, an association, a trust or other entity or organization, including a federal, state, local or foreign Governmental Authority or political subdivision or an agency or instrumentality thereof.
Pre-Closing Tax Period” means any taxable period ending on or before the Closing Date and the portion of any Straddle Period ending on and including the Closing Date.
Purchase Price” has the meaning set forth in Section 2.5.
Purchased Assets” has the meaning set forth in Section 2.1.
Representatives” means, with respect to any Person, the officers, directors, employees, accountants, counsel, consultants, advisors and agents and other authorized representatives of such Person, in each case acting in such capacity.
Retinol” means [*] and meeting the product specifications agreed by [*].
Review Period” has the meaning set forth in Section 3.5.2.
Sandalwood” means [*] and meeting the product specifications agreed by [*].
Sclareol” means [*] and meeting the product specifications agreed by [*].
Seller” has the meaning set forth in the preamble to this Agreement.
Shortfall Payment” has the meaning set forth in Section 3.5.4.



Specified IP Matters” means all Liabilities related to or arising out of any indemnification obligations set forth in the Firmenich Collaboration Agreement or the Givaudan Collaboration Agreement to the extent relating to any facts, circumstances, occurrences or developments that existed or occurred prior to the Closing Date.
Straddle Period” means a taxable period that includes but does not end on the Closing Date.
Subsidiary” means with respect to a Party, any corporation, or other business entity that, either directly or indirectly, is controlled by such Party by way of ownership of the voting stock of such entity.
Supply Agreement” means the supply agreement pursuant to which Seller will supply Buyer with its requirements for the Molecules, substantially in the form attached as Exhibit C hereto.
Takasago Agreement” means Farnesene Supply Agreement by and between Amyris and Takasago International Corporation dated December 18, 2015.
Tax” or “Taxes” means all U.S. and non-U.S., federal, state, provincial, municipal or other taxes, fees, levies, duties, tariffs, imposts and other assessments or charges of whatever kind (including taxes or other charges on, or measured by or with respect to, income or sales, use, excise, stamp, transfer, alternative minimum, estimated, property, windfall or other profits, value added, recording, registration, intangible, documentary, goods and services, escheat or unclaimed property, real estate, payroll, employment, social security, license, customs’ duties or similar fees, ad valorem, net worth, gains, gross receipts, withholding, environmental, and franchise taxes) and including repayments of any grants, subsidies, state aid or similar amounts from a Governmental Authority, together with any interest, penalties or additions payable in connection with such taxes, fees, levies, duties, tariffs, imposts and other assessments or charges imposed by any Governmental Authority or taxing authority, whether disputed or not and including any obligation to indemnify or otherwise assume or succeed to the Tax Liability of any other Person (other than any such obligation arising pursuant to a customary commercial contract entered into in the ordinary course of business with unrelated Persons the principal subject matter of which is not Taxes).
Tax Return” means, with respect to any jurisdiction (foreign or domestic), any return, declaration, statement, report, claim for refund, information return, declaration of estimated Tax or other documents filed or required to be filed with respect to Taxes, and any schedule or attachment thereto and any amendment thereof.
Third Party” means any Person other than the Parties and their respective Affiliates.
Transaction Documents” means, collectively, this Agreement, the Bill of Sale and Assignment and Assumption Agreement, the License and Drawing Rights Agreement and the Supply Agreement and any other documents, certificates, instruments, amendments, schedules and agreements executed in connection with, or required to be delivered by, any of the foregoing.



Transfer Documents” means, collectively, such deeds, bills of sale, assignments, assumptions (including Liability assumption agreements), affidavits and other instruments of sale, conveyance, transfer and assignment between Seller, on the one hand, and Buyer, on the other hand, in form and substance reasonably satisfactory to Seller and Buyer, as may be reasonably necessary or advisable under the Laws of the relevant jurisdictions to effect the Contemplated Transactions.
Transfer Taxes” means any and all transfer, documentary, sales, use, stamp, registration, value added, recording and other similar Taxes and fees, together with any interest, penalties or additions thereto, incurred in connection with the Contemplated Transactions; provided, however, that Transfer Taxes shall not include Taxes based upon or calculated by reference to income, profits or gains (including any such Taxes collected or assessed through withholding).
[*]
ARTICLE 2
PURCHASE AND SALE OF ASSETS
2.1 Purchase and Sale of Assets. Upon the terms and subject to the conditions of this Agreement, at the Closing, Seller shall sell, transfer, assign, convey and deliver to Buyer, and Buyer shall purchase and accept from Seller, all of Seller’s right, title and interest in, to and under all assets, properties, rights and interests of any kind and description (whether real, personal or mixed, tangible or intangible, or fixed, contingent or otherwise), as expressly set forth in this Section 2.1, wherever located and by whomever possessed (but excluding the Excluded Assets), as such assets exist on the Closing Date (collectively, the “Purchased Assets”), free and clear of all Encumbrances (other than Permitted Encumbrances). The Purchased Assets shall consist of the following:
2.1.1.the Assumed Contracts;
2.1.2.all books, records, manuals, reports, business plans, data, mailing lists, customer lists, supplier lists, price lists, sales records, vendor data, marketing information and procedures, sales and customer files, current product material, standard forms of documents and manuals of operations or business procedures (other than Intellectual Property), in each case to the extent relating solely to the Purchased Assets or the Assumed Liabilities, whether in hard copy or electronic format, including the Business Tax Records but excluding the Excluded Books and Records (collectively, the “Business Books and Records”), including the technical transfer packages set forth on Schedule 2.1.2; provided, that Seller may temporarily retain possession of and may utilize any Business Books and Records related to the manufacturing of the Molecules on behalf of Buyer to the extent required to comply with its obligations under the Supply Agreement until such time as Buyer has elected thereunder to manufacture one or more of the Molecules, at which time Seller shall deliver all such Business Books and Records (or portions thereof) solely applicable to said Molecules, which shall include such technical transfer packages, to Buyer; provided, further, that Seller shall not be required to deliver Business Tax Records to the extent separate books and records comprising the Business Tax Records are not readily available, but will provide reasonable access to the portions of such books and records comprising the Business Tax Records from time to time, as may be reasonably requested by Buyer.



2.1.3.all (a) rights under or pursuant to all express or implied warranties, representations and guarantees made by suppliers, vendors or other third parties in favor of Seller with respect to any of the other Purchased Assets, and (b) claims, causes of action, rights of recovery, rights of offset or set-off, defenses, warranties and indemnities in favor of Seller from or against any third parties, whether known or unknown, contingent or otherwise, including any encumbrances, security interests, pledges or other rights to payment or to enforce payment, to the extent arising out of the operation, lease or use of the Purchased Assets;
2.1.4.all trade accounts and notes receivable, any other receivables and other rights to receive payment to the extent arising out of the sale or other disposition of goods or performance of services by the Business pursuant to the Assumed Contracts, including the full benefit of all security for such receivables, and any claims, remedies or other rights related to any of the foregoing as listed on Schedule 2.1.4 (collectively, the “Accounts Receivable”);
2.1.5.certain finished goods inventory used, or held for use, in the Business listed on Schedule 2.1.5 (collectively, the “Inventory”); and
2.1.6.all goodwill and other intangible property (other than Intellectual Property) to the extent arising out of the operation, ownership, lease or use of the Purchased Assets, including the customer relationships of the Business to the extent related to the Business.
Nothing in this Section 2.1 shall obligate Buyer to assume any Liability related to Seller or any of its Affiliates, the Business, the Purchased Assets or otherwise, unless Buyer expressly assumes such Liability pursuant to Section 2.2.
2.2.Assumed Liabilities. At the Closing, on the terms and subject to the conditions of this Agreement, and as additional consideration for the Purchased Assets, Buyer shall assume and be liable for, effective as of the Closing, and thereafter shall pay, perform and discharge when due, all Liabilities of Seller to the extent first and solely arising out of or under the Purchased Assets after the Closing, but excluding any Excluded Liabilities (collectively, the “Assumed Liabilities”).
2.3.Excluded Assets. Notwithstanding anything to the contrary contained in Section 2.1, Seller and Buyer acknowledge and agree that the Purchased Assets shall not include, and Seller is not selling, assigning, transferring or conveying to Buyer any right, title or claim related to, or interest in, any of the following assets (collectively, the “Excluded Assets”):
2.1.all real property interests and equipment of Seller, raw materials inventory and other tangible personal property (provided, that, for the avoidance of doubt, the foregoing shall not be deemed to include any Business Books and Records);
2.2.all cash and cash equivalents of Seller;
2.3.(a) all corporate minute books (and other similar corporate records) of Seller, (b) any books and records to the extent relating to the other Excluded Assets, (c) all Tax Returns and other Tax records (including work papers) of Seller (but excluding all Business Tax Records) and (d) any books, records or other materials or permits that Seller (i) is required by Law to retain (copies of which, to the extent relating to the Purchased Assets or the Assumed Liabilities and to



the extent not prohibited by Law, will be made available to Buyer upon Buyer’s reasonable request) or (ii) is prohibited by Law from delivering to Buyer (collectively, the “Excluded Books and Records”); and
2.4.all Contracts (and all rights thereunder) other than the Assumed Contracts.
2.2.Excluded Liabilities. Buyer shall not assume, nor become responsible for, any Liabilities of Seller other than the Assumed Liabilities (collectively, the “Excluded Liabilities”), each of which shall remain the Liability of Seller. For the avoidance of doubt, Excluded Liabilities includes all Liabilities arising out of, in respect of or relating to:
2.1.the ownership of the Purchased Assets or the operation or conduct of the Business prior to the Closing;
2.2.all trade accounts payable, regardless of when incurred, billed or imposed, of Seller;
2.3.the Excluded Assets;
2.4.(a) the portion of the Transfer Taxes that are the responsibility of Seller pursuant to Section 6.2.1, (b) all Taxes of or imposed on Seller for any Tax period, and (c) any Taxes of or with respect to the Business or the Purchased Assets for any Pre-Closing Tax Period, (which in the case of a Straddle Period, shall be allocated to the Pre-Closing Tax Period in accordance with the methodology set forth in Section 6.2.3) including any such Taxes that Buyer is liable for as withholding agent or transferee;
2.5.any indebtedness of Seller;
2.6.all Liabilities related to the employment or service (or the termination of employment or service) of any Person at any time by Seller, including all Liabilities arising under, pursuant to or in connection with, any Seller employee plan or any other compensation or benefit plan, program, policy, Contract or other arrangement that is or was at any time established, sponsored, maintained or contributed to (or required to be contributed to) by Seller or with respect to which Seller has or could have any Liability or obligation (whether current or contingent);
2.7.this Agreement and the other Transaction Documents (other than Liabilities or obligations attributable to any failure by Buyer to comply with the terms hereof or thereof); and
2.8.the Specified IP Matters; and
2.9.all Liabilities of Seller outstanding at Closing with respect to the supply of any remaining quantity of the Initial Order or Expedited Initial Order pursuant to Section 3.4 of the Takasago Agreement to Takasago International Corporation for which payment, as the Extension Credit, has been made pursuant to Section 4.1(e) of the Takasago Agreement.
2.2.Initial Purchase Price.
2.5.1.In consideration of the sale and transfer of the Purchased Assets, Buyer agrees to assume the Assumed Liabilities and pay to Seller, a non-refundable Purchase Price of One Hundred Fifty Million ($150,000,000) US Dollars (the “Initial Purchase Price”), settlement of



which shall be made in accordance with the Funds Flow Instruction Letter mutually agreed and delivered by the Parties on the date hereof. The portion of the Initial Purchase Price payable to Seller shall be paid by wire transfer of immediately available funds in accordance with Funds Flow Instruction Letter.
2.5.2.The Parties acknowledge and agree that the Initial Purchase Price has been calculated in part based on the estimated Inventory and Accounts Receivable to be delivered hereunder. To the extent that the aggregate value of the Inventory and the Accounts Receivable delivered at the Closing is less than or more than $[*], the Earn-Out Payment for calendar year 2022, or in later years to the extent the 2022 Earn-Out Payment is insufficient, will be reduced or increased by such difference.
2.6.    Withholding. Notwithstanding anything in this Agreement to the contrary, Buyer shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to the Agreement or otherwise pursuant to the Contemplated Transactions any amounts that it is required to deduct and withhold with respect to the making of such payments under any provision of applicable Law; provided, that Buyer shall (a) provide Seller with a written notice of its intention to withhold, along with reasonable details regarding the provisions of applicable Law that require such deduction or withholding, at least five (5) days prior to any such withholding, (b) use commercially reasonable efforts to cooperate with Seller in order to minimize any such withholdings or deductions (including by accepting any properly completed and duly executed documentation that is provided by Seller), (c) timely pay any withheld Taxes to the appropriate Governmental Authority and (d) provide proof of payment the withheld Taxes to Seller within fifteen (15) days following the date of such payment. Any such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Seller. In the event that (a) Buyer assigns any or all rights under this Agreement to an Affiliate pursuant to Section 8.4 and (b) Buyer (or its Affiliate) is obligated to deduct and withhold from any amounts otherwise payable pursuant to the Agreement by Buyer arises under applicable Law, Buyer shall pay to Seller an additional amount so that the net amount received by Seller will equal the full amount which would have been received Seller had no such deductions or withholdings been made; provided, however, that no additional amounts shall be required to be paid to Seller under this Section 2.6 to the extent that withholding would have otherwise been required had Buyer acquired the Purchased Assets directly and not assigned all or a portion of its rights to the applicable Affiliate.
ARTICLE 3
CLOSING; CLOSING DELIVERIES
3.1.Closing. The closing of the Contemplated Transactions (the “Closing”) shall take place through the electronic exchange of deliveries and executed documents as the Parties agree (including remotely by exchange of signature pages by facsimile or in electronic format, including in PDF or similar format) on the date hereof (the “Closing Date”). The Closing will be deemed to occur at 12:01 a.m., Central European Time, on the Closing Date.
3.2.Deliveries by Buyer. At Closing, Buyer shall deliver, or cause to be delivered, to Seller, the following:
3.1the Bill of Sale and Assignment and Assumption Agreement, duly executed by Buyer;



3.2the License and Drawing Rights Agreement, duly executed by Buyer;
3.3the Supply Agreement, duly executed by Buyer;
3.4an annex to the written Consents of each of Givaudan and Firmenich to the assignment of the Assumed Contracts to which it is a party containing additional terms agreed to by Buyer, Seller and, as applicable, Givaudan and Firmenich, and duly executed by Buyer;
3.5the Initial Purchase Price, paid in accordance with Section 2.5.
3.3Deliveries by Seller. At Closing, Seller shall deliver, or cause to be delivered, to Buyer:
3.3.1.the Bill of Sale and Assignment and Assumption Agreement, duly executed by Seller;
3.3.2.the License and Drawing Rights Agreement, duly executed by Seller;
3.3.3.the Supply Agreement, duly executed by Seller;
3.3.4.a written Consent by each of Givaudan, Firmenich and Takasago with respect to the assignment of the Assumed Contracts to which it is a party to Buyer, and, in the case of Givaudan and Firmenich an Annex containing additional terms agreed to by Buyer, Seller and, as applicable, Givaudan and Firmenich, and duly executed by Seller;
3.3.5.a valid and duly executed IRS Form W-9 of Seller;
3.3.6.each of the items set forth on Schedule 3.3;
3.3.7.a complete and accurate electronic copy of the contents of the Data Room as at 9:00 a.m. New York time on the Business Day prior to the date of this Agreement, which for the avoidance of doubt will be delivered in Switzerland; and
subject to Section 3.4, physical possession of all tangible Purchased Assets, together with all such other Transfer Documents to vest in Buyer good and marketable title to all of the Purchased Assets, free and clear of all Encumbrances (other than Permitted Encumbrances).
3.4.Further Assurances. Seller shall use its reasonable best efforts to identify and locate the documents and records included in the Purchased Assets and at Closing will deliver the documents and records so located. From time to time, at Buyer’s or Seller’s request, whether on or after the Closing Date, Buyer or Seller, as the case may be, shall, for no further consideration, execute and deliver such further instruments of conveyance, transfer and assignment and take such other commercially reasonable actions as Buyer or Seller, as the case may be, may reasonably require of the other Party to more effectively assign, convey and transfer to Buyer the Purchased Assets and effect the assumption by Buyer of the Assumed Liabilities, in each case on the terms and conditions set forth in this Agreement.
3.5.Earn-Out Payments. Upon the terms and subject to the conditions of this Agreement, as additional consideration for the transfer of the Purchased Assets to Buyer pursuant to Section 2.1, Buyer shall pay to or for the account of the Seller an amount in cash calculated with respect to the Earn-Out Period as follows:



3.5.1.Subject to Section 3.5.4 and, Section 3.5.5 and Section 3.5.7 for the calendar year 2024, for each calendar year beginning on January 1, 2022 through December 31, 2024 (the “Earn-Out Period”), Buyer shall make the payments described in this Section 3.5.1 (each such annual amount, an “Earn-Out Payment”) in the manner set forth in Section 3.5.3; provided that the aggregate Earn-Out Payments to be paid pursuant to this Section 3.5 shall under no circumstances exceed $235,000,000 (the “Aggregate Earn-Out Cap”) (excluding any adjustment under Section 2.5.2):
(a)The Earn-Out Payment for calendar year 2022 shall be equal to (i) 9.0 multiplied by (ii) Annual Launch Business EBITDA for calendar year 2022;
(b)The Earn-Out Payment for calendar year 2023 shall be paid only if Annual Launch Business EBITDA for calendar year 2023 exceeds Annual Launch Business EBITDA for calendar year 2022. In such event, the Earn-Out Payment for calendar year 2023 shall be equal to (i) 9.0 multiplied by (ii) the difference of (A) Annual Launch Business EBITDA for calendar year 2023, minus (B) Annual Launch Business EBITDA for calendar year 2022; provided, that if Annual Launch Business EBITDA for calendar year 2023 is higher than the Launch Business Forecast Amount for calendar year 2024, such Earn-Out Payment shall be reduced by the amount of such difference;
(c)The Earn-Out Payment for calendar year 2024 shall be paid only if Annual Launch Business EBITDA for calendar year 2024 exceeds the greater of (x) Annual Launch Business EBITDA for calendar year 2022 and (y) Annual Launch Business EBITDA for calendar year 2023. In such event, the Earn-Out Payment for calendar year 2024 shall be equal to (i) 9.0 multiplied by (ii) the difference of (A) Annual Launch Business EBITDA for calendar year 2024, minus (B) the greater of (x) Annual Launch Business EBITDA for calendar year 2022 and (y) Annual Launch Business EBITDA for calendar year 2023.
3.5.2.As soon as reasonably practicable following each of the calendar years 2022, 2023 and 2024, Buyer will within sixty (60) days after the end of such calendar year, prepare and deliver to the Buyer a written schedule (the “Earn-Out Schedule”) setting forth its good faith calculations of Annual Launch Business EBITDA and the Earn-Out Payment for such calendar year, including the basis for such computations set forth in reasonable detail. Upon receipt of the Earn-Out Schedule, the Seller shall have thirty (30) days (the “Review Period”) to review the Earn-Out Schedule and related computations of Annual Launch Business EBITDA and the Earn-Out Payment. In connection with such review of the Earn-Out Schedule, Buyer shall, and shall cause the Launch Business to make available, to the Seller and its Representatives such documents, books, records, work papers, facilities, personnel and other information of Buyer and the Launch Business, in each case as the Seller may reasonably request in order to permit the timely review of the Earn-Out Schedule in accordance with this Section 3.5.2. If the Seller has accepted such EarnOut Schedule in writing or has not given written notice to Buyer setting forth in reasonable detail any objection of the Seller to the Earn-Out Schedule (an “Earn-Out Payment Statement of Objections”) prior to the expiration of the Review Period, then such Earn-Out Schedule shall be final and binding upon the parties, and the Earn-Out Payment set forth on such Earn-Out Schedule shall be deemed to be the final Earn-Out Payment for the Earn-Out Period. If the Seller delivers an Earn-Out Payment Statement of Objections during the Review Period, Buyer and the Seller shall use their reasonable efforts to agree on the amount of the Earn-



Out Payment for the Earn-Out Period within fifteen (15) days following the receipt by Buyer of the Earn-Out Payment Statement of Objections. If the parties are unable to reach an agreement as to such amounts within such 15 day period, then the matter shall be submitted to a mutually agreed internationally recognized certified public accounting firm that has not performed accounting, tax or auditing services for Buyer or Seller or any of their respective Affiliates during the past three years (the “Arbitrating Accountant”). The Arbitrating Accountant’s function will be to resolve each element of the EarnOut Payment Statement of Objections that has not been resolved by Buyer and Seller, to revise the Earn-Out Schedule to reflect such resolutions and to calculate the Earn-Out Payment, if any, based on the elements and amounts reflected on the revised Earn-Out Schedule. The Arbitrating Accountant shall make such determination within fifteen (15) days following the submission of the matter to the Arbitrating Accountant for resolution, and such determination shall be final and binding upon Buyer and the Seller. In making such determination, the Arbitrating Accountant will be bound by the provisions of this Agreement and may not revise any element of the Earn-Out Payment Statement of Objections that is not contested in the Earn-Out Payment Statement of Objections or assign a value to any disputed element of the Earn-Out Payment Statement of Objections greater than the greatest value for such item claimed by either party or less than the smallest value for such item claimed by either party. Each of the Arbitrating Accountant’s decision, the revised Earn-Out Payment Statement of Objections and the revised calculation of the Earn-Out Payment, if any, will be final and binding upon the parties, and judgment may be entered on the award. Buyer and Seller shall share the fees and expenses of the Arbitrating Accountant in inverse proportion to the relative amounts subject to the Earn-Out Payment Statement of Objections determined in favor of such party, in accordance with the following formulas: (i) Seller shall pay a portion of such fees and expenses equal to the total fees and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Earn-Out Payment Statement of Objections resolved in favor of Buyer and the denominator of which is the total dollar amount subject to the Earn-Out Payment Statement of Objections and (ii) Buyer shall pay a portion of such fees and expenses equal to the total fees and expenses multiplied by a fraction, the numerator of which is the dollar amount subject to the Earn-Out Payment Statement of Objections resolved in favor of Seller and the denominator of which is the total dollar amount subject to the Earn-Out Payment Statement of Objections.
3.5.3.If Seller is entitled to an Earn-Out Payment for any of the calendar years 2022, 2023 or 2024, Buyer shall pay such Earn-Out Payment by wire transfer of immediately available funds, to the Seller or to such accounts as designated by the Seller in writing to Buyer, no later than March 31 of the immediately following calendar year (i.e., the Earn-Out Payment for calendar year 2022 shall be paid no later than March 31, 2023); provided, that if the amount of such Earn-Out Payment has not been finally determined in accordance with Section 3.5.2 prior to March 31, such EarnOut Payment shall be paid within 10 days following the date on which such Earn-Out Payment has been finally determined.
3.5.4.In the event that Annual Launch Business EBITDA for the calendar year 2024 is less than Annual Launch Business EBITDA for the calendar year 2022 or the calendar year 2023, then Seller shall pay to Buyer an amount equal to (a) 9.0 multiplied by (b) the amount by which Annual Launch Business EBITDA for the calendar year 2024 is less than the greater of (i) the Annual Launch Business EBITDA for the calendar year 2022 or (ii) the Annual Launch Business



EBITDA for the calendar year 2023 (such resulting product of clauses (a) and (b), the “Shortfall Payment”). If the Shortfall Payment is greater than $0, Seller shall pay the Shortfall Payment to Buyer by wire transfer of immediately available funds, to Buyer or to such accounts as designated by Buyer in writing to Seller, no later than March 31, 2025; provided, that if Annual Launch Business EBITDA for the calendar year 2024 has not been finally determined in accordance with Section 3.5.2 prior to March 31, 2025, such Shortfall Payment shall be paid within 10 days following the date on which Annual Launch Business EBITDA for the calendar year 2024. Notwithstanding the foregoing, Buyer may elect, in its sole discretion, to reduce the Earn-Out Payment for calendar year 2024 by the amount of the Shortfall Payment, and in such event, no further Shortfall Payment shall be required hereunder.
3.5.5.The Earn-Out Payment for the calendar year 2022 shall be reduced on a dollar-for- dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement (excluding [*]) during the calendar years 2021 and 2022 are less than the target amounts for such periods set forth on Schedule 3.5.5 (the “2022 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2022 Value Share Guarantee Amount shall be zero ($0) dollars. The Earn-Out Payment for the calendar year 2023 shall be reduced on a dollar-for- dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement during the calendar year 2023 is less than the target amounts for such period set forth on Schedule 3.5.5 (the “2023 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2023 Value Share Guarantee Amount shall be zero ($0) dollars. The Earn-Out Payment for the calendar year 2024 shall be reduced on a dollar-for-dollar basis by the amount by which the share profits actually paid by Firmenich to Buyer pursuant to Section 21.2 of the Firmenich Collaboration Agreement during the calendar year 2024 is less than the target amounts for such period set forth on Schedule 3.5.5 (the “2024 Value Share Guarantee Amount”); provided that if such actual payments are equal to 90% or more of such target amounts, the 2024 Value Share Guarantee Amount shall be zero ($0) dollars.
3.5.6.In the event that the Earn-Out Payment for any of the calendar years 2022, 2023 or 2024 is less than any of the 2022 Value Share Guarantee Amount, 2023 Value Share Guarantee Amount or 2024 Value Share Guarantee Amount (each, a “Guarantee Amount”), then Seller shall pay the difference of such Earn-Out Payment and Guarantee Amount to Buyer by wire transfer of immediately available funds or to such account as designated by Buyer in writing to Seller.
3.5.7.Notwithstanding the foregoing, subj ect to the Aggregate Earn-Out Cap, in the event that the aggregate volume of [*]sold by Buyer during the years 2022 through 2024 is equal to or less than [*], which reflects [*]% of the current forecast:
(a)the aggregate amount of Earn-Out Payments to which Seller shall be entitled to receive hereunder shall be no greater than an amount equal to the sum of: (i) (A) 8.0 multiplied by (B) the lesser of (x) $20,000,000 and (y) Annual Launch Business EBITDA for calendar year 2024, plus (ii) (I) 9.0 multiplied by (II) the extent to which Annual Launch Business EBITDA for calendar year 2024 exceeds $20,000,000 (the “[*] Adjustment Cap”), and the Earn-



Out Payment for the calendar year 2024 shall be reduced as may be necessary to give effect to the [*] Adjustment Cap; and
(b)if the aggregate amount of Earn-Out Payments previously paid to Seller under this Section 3.5 is greater than the [*] Adjustment Cap, Seller shall refund any such excess amounts by wire transfer of immediately available funds, to Buyer or to such accounts as designated by Buyer in writing to Seller, no later than March 31, 2025.
3.5.8.During the Earn-Out Period Buyer shall, and shall cause the Launch Business to maintain such books and records related to the Launch Business (including with respect to the inputs for the Launch Business Forecast Amount) sufficient to allow independent verification of the results of the operations of the Launch Business, including for purposes of calculating the Earn-Out Payment and the Launch Business Forecast Amount for each year. Buyer shall not, directly or indirectly, take any actions, or omit to take any actions, in bad faith for the purpose of avoiding or reducing an Earn-Out Payment.
3.5.9.It is the intention of Buyer and Seller that the sale and purchase of the Purchased Assets pursuant to this Agreement in exchange for Seller’s right to receive the Earn-Out Payments shall qualify as an “installment sale” within the meaning of Section 453 of the Code.
3.6.Wrong Pockets.
3.6.1.If at any time after the Closing, Seller (a) receives any payment, remittance or other amount in respect of any Purchased Asset or Assumed Liability or (b) is in possession of any Purchased Assets, then, in each case, Seller shall transfer such funds or assets to Buyer (or Buyer’s designee) as soon as reasonably practicable upon identification of such funds or assets, for no additional consideration; it being acknowledged and agreed that Buyer shall have already paid full consideration for all such funds and assets by payment of the Purchase Price. Prior to any such transfer, Seller shall preserve the value of and hold in trust for the use and benefit of Buyer of such funds or assets and provide to Buyer all of the benefits arising from such funds or assets and otherwise cause such funds or assets to be used as reasonably instructed by Buyer.
3.6.2.If at any time after the Closing, Buyer (a) receives any payment, remittance or other amount in respect of any Excluded Asset or Excluded Liability or (b) is in possession of any Excluded Assets that were transferred to Buyer in error, then, in each case, Buyer shall promptly transfer such funds or assets to Seller (or Seller’s designee) as soon as reasonably practicable upon identification of such funds or assets, for no consideration (net of any reasonable fees and expenses incurred by as a result of such error). Prior to any such transfer, Buyer shall preserve the value of and hold in trust for the use and benefit of Seller of such funds or assets and provide to Seller all of the benefits arising from such funds or assets and otherwise cause such funds or assets to be used as reasonably instructed by Seller.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller hereby represents and warrants to Buyer, as of the date of this Agreement, that:



4.1.Organization and Authority. Seller is a corporation validly existing and in good standing under the laws of the State of Delaware. Seller has all necessary corporate power and authority to enter into, execute and deliver this Agreement and each other Transaction Document to which it is a party, to carry out its obligations hereunder and thereunder, and to consummate the Contemplated Transactions. The execution and delivery by Seller of this Agreement and of each other Transaction Document to which it is a party, the performance by Seller of its obligations hereunder and thereunder and the consummation by Seller of the Contemplated Transactions have been authorized by all requisite corporate action. This Agreement and each other Transaction Document to which Seller is a party has been duly and validly executed by Seller, and, assuming the due authorization, execution and delivery by Buyer, this Agreement and each such other Transaction Document is a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws now or hereafter in effect relating to or affecting creditors’ rights generally and rules of law and general equitable principles, including those governing specific performance, injunctive relief and other equitable remedies (the “Enforceability Exceptions”).
4.2.No Conflicts; Consents. The execution, delivery and performance of this Agreement and each other Transaction Document to which Seller is a party by Seller do not and will not, and the consummation of the Contemplated Transactions and compliance with the terms and conditions hereof and thereof by Seller do not and will not: (a) violate, conflict with or result in the breach of the organizational documents of Seller; (b) result in a material breach, material violation of, or material default under, or create in any Person the right to terminate, cancel, accelerate or modify, require any Consent under, or result in the loss of any material benefit to which Seller is entitled under (in each case whether after the giving of notice or the lapse of time of both), any Assumed Contracts or any other Contract to which any of the Purchased Assets is subject or Seller is bound;
(c)conflict with or violate, in any material respect, any Law applicable to Seller or the Purchased Assets; or (d) result in the creation of an Encumbrance upon any of the Purchased Assets except, in the case of clauses (b), (c) and (d), as would not, individually or in the aggregate, reasonably be expected to (i) prevent, materially delay or materially and adversely affect the ability of Seller to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions, (ii) result in material Liability to Buyer or (iii) materially impair the operation of the Business as currently conducted.
4.3.Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by Seller, and the consummation of the Contemplated Transactions by Seller, do not require any Consent of any Governmental Authority or other Person, except to the extent failure to obtain such Consent would not (i) prevent, materially delay or materially and adversely affect the ability of Seller to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions, (ii) result in material Liability to Buyer or (iii) materially impair the operation of the Business as currently conducted. The Business does not (i) produce, design, test, manufacture, fabricate, or develop “critical technologies” as that term is defined in 31 C.F.R. § 800.215; (ii) perform the functions as set forth in column 2 of Appendix A to 31 C.F.R. part 800 with respect to covered investment “critical infrastructure”; or (iii) maintain or collect, directly or indirectly, “sensitive personal data” as that term is defined in 31 C.F.R. § 800.241; and, therefore, in turn, none of the



Persons conducting the Business is a “TID U.S. business” within the meaning of 31 C.F.R. § 800.248.
4.4.Compliance with Law; Litigation and Claims. Seller and each of its Affiliates is not in default or violation of any Law in any material respect applicable to the Purchased Assets or the Assumed Liabilities or by which any of the Purchased Assets or Assumed Liabilities is bound. There is no Action pending or, to the Knowledge of Seller, threatened, against Seller, related to the Purchased Assets or the Assumed Liabilities. There are no outstanding writs, injunctions, decrees, arbitration unsatisfied decisions, unsatisfied judgments or orders issued by any Governmental Authority outstanding against Seller or to which any of the Purchased Assets or Assumed Liabilities is subject or bound.
4.5.Purchased Assets.
4.5.1.Title to Purchased Assets. Seller has good and valid title to and the right to transfer (or cause to be transferred) all Purchased Assets, in accordance with the terms of this Agreement, free and clear of all Encumbrances (other than Permitted Encumbrances).
4.5.2.Completeness of Purchased Assets. The Purchased Assets, together with the Intellectual Property rights licensed to Buyer under the License and Drawing Rights Agreement, constitute all of the assets, rights, privileges and properties necessary for Buyer to conduct the Business in substantially the same manner immediately following the Closing as currently conducted by Seller, except that Buyer acknowledges that it is not purchasing any real property, manufacturing equipment or manufacturing Contracts or any other Excluded Assets that are necessary for Buyer to conduct the Business.
4.6.Tax Matters. All material Tax Returns required to have been filed by Seller or otherwise with respect to the Purchased Assets have been duly filed, and all Taxes required to have been paid by Seller or otherwise with respect to or that could become an Encumbrance on the Purchased Assets have been paid. There are no rulings, settlement or closing agreements or other transactions or agreements entered into prior to the Closing with respect to Taxes pertaining to the Purchased Assets that would bind Buyer or give rise to any Tax liability for Buyer or its Affiliates after the Closing. There are no Encumbrances for Taxes on any of the Purchased Assets, other than Permitted Encumbrances. There are no audits, examinations, investigations or other proceedings with respect to Taxes pending or threatened relating to or that could result in an Encumbrance on the Purchased Assets, and no claim has been made by a Governmental Authority that Tax Returns with respect to the Purchased Assets should be filed which have not been filed. None of the Purchased Assets are “tax-exempt use property” within the meaning of Section 168(h) of the Code, are “tax-exempt bond financed property” within the meaning of Section 168(g) of the Code, secure any debt the interest of which is tax-exempt under Section 103(a) of the Code or are subject to a “section 467 rental agreement” within the meaning of Section 467 of the Code (or in each case, similar or corresponding provisions of applicable state Tax Law). Notwithstanding anything in this Agreement to the contrary, the representations and warranties contained in this Section 4.6 (i) shall not apply to the extent that a breach of such representations or warranties would not result in any Taxes or other liabilities or obligations for Buyer and Buyer’s Affiliates and also would not result in any Encumbrances on the Purchased Assets and (ii) constitute the sole representations and warranties being made by Seller with respect to Taxes.



4.7.Assumed Contracts. Seller has made available to Buyer true and complete copies of all Assumed Contracts. Each Assumed Contract is a valid and binding obligation of Seller and, to the Knowledge of Seller, the other party thereto, and is in full force and effect, in each case subject to the Enforceability Exceptions. Neither Seller nor, to the Knowledge of Seller, any other party thereto is in material breach of, or material default under, any Assumed Contract, and no event has occurred that, with the giving of notice or lapse of time or both, would constitute a material breach or material default thereunder. Seller has not received written notice of termination, cancellation or non-renewal with respect to any Assumed Contract. No Assumed Contract has been amended or otherwise modified. Other than the Assumed Contracts, there are no Contracts between Seller, on the one hand, and any of Givaudan, Firmenich or Takasago, on the other hand, with respect to the Business.
4.8.Inventory. As of the Closing Date, the Inventory (a) is good, saleable and merchantable in the ordinary course of business with a shelf life of no less than [*], and [*] for volumes of Manool delivered at Closing exceeding [*], (b) was produced or manufactured in accordance with the specifications for the Molecule as set forth in material compliance with applicable Law and the Assumed Contracts and (c) is not adulterated and is of suitable quality. The Inventory has a fair market value of no less than $1,909,500, calculated in a manner consistent with GAAP as applied in Seller’s historical practice.
4.9.R&D Obligations. Seller has completed, and is in compliance with all of the obligations under the Assumed Contracts with respect to, all research and development actions and obligations in connection with all of the applicable products that have been commercialized by Givaudan and Firmenich.
4.10.Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of any of Seller for which Buyer would have any Liability.
4.11 No Implied Representations. Notwithstanding anything to the contrary contained in this Agreement, Seller has not made any representation or warranty whatsoever, express or implied, other than those representations and warranties of Seller expressly set forth in this Article 4. Neither Seller nor any of its Affiliates nor any of their respective Representatives make any representation or warranty to Buyer or any of its Affiliates or any of their respective Representatives with respect to any forward-looking projections, estimates or budgets heretofore made available to Buyer or any of its Affiliates or any of their respective Representatives of future revenues, expenses or expenditures or future results of operations of the Business or the Purchased Assets any other information or documents made available to Buyer or any of its Affiliates or any of their respective Representatives.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer represents and warrants to Seller as of the date of this Agreement:
5.1.Organization and Authority. Buyer is a corporation duly organized and in good standing under the laws of Switzerland. Buyer has all necessary corporate power and authority to enter into, execute and deliver this Agreement and each other Transaction Document to which it is a



party, to carry out its obligations hereunder and to consummate the Contemplated Transactions. The execution and delivery by Buyer of this Agreement and each other Transaction Document to which it is a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the Contemplated Transactions have been authorized by all requisite corporate action on the part of Buyer. This Agreement and each other Transaction Document to which Buyer is a party has been duly and validly executed and delivered by Buyer, and, assuming the due authorization, execution and delivery by Seller, this Agreement and each such other Transaction Document is a legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, subject to the Enforceability Exceptions.
5.2.No Conflicts; Consents. The execution, delivery and performance of this Agreement and of each other Transaction Document to which Buyer is a party by Buyer do not and will not, and the consummation of the Contemplated Transactions and compliance with the terms and condition hereof and thereof by Buyer do not and will not: (a) violate, conflict with or result in the breach of the organizational documents of Buyer; (b) result in a breach, violation of or default under (whether after the giving of notice or the lapse of time or both), or create in any Person the right to terminate, cancel, accelerate or modify, or require any Consent under, any Contract to which Buyer is a party or to which its properties or assets are subject; (c) conflict with or violate any Law applicable to Buyer, except, in the case of clauses (b) and (c), as would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or materially and adversely affect the ability of Buyer to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions.
5.3.Consents and Approvals. The execution, delivery and performance of this Agreement and the other Transaction Documents by Buyer, and the consummation of the Contemplated Transactions by Buyer, do not require any Consent of any Governmental Authority or other Person, except to the extent failure to obtain such Consent would not prevent, materially delay or materially and adversely affect the ability of Buyer to carry out its obligations under this Agreement or the other Transaction Documents or to consummate the Contemplated Transactions.
5.4.Sufficient Funds. Buyer has full financial capacity to comply with the payment obligations provided in this Agreement.
5.5.No Other Representations. Except for the representations and warranties expressly set forth in Article 4, Buyer acknowledges that none of the Seller nor any of its Affiliates nor any of their respective Representatives nor any other Person makes, and Buyer acknowledges that it has not relied upon or otherwise been induced by, any express or implied representation or warranty with respect to Seller, the Business or the Purchased Assets or with respect to any other information provided or made available to Buyer or its Affiliates or their respective Representatives in connection with the Contemplated Transactions, including any information, documents, projections, forecasts or other material made available to Buyer or its Affiliates or their respective Representatives in certain “data rooms” or management presentations in expectation of the Contemplated Transactions or the accuracy or completeness of any of the foregoing, except, in each case for the representations and warranties expressly set forth in Article 4 hereof.



ARTICLE 6
COVENANTS
6.1.Expenses. All expenses, including the fees of any attorneys, accountants, investment bankers or others engaged by a Party, incurred in connection with this Agreement and the Contemplated Transactions, shall be paid by the Party incurring such fees and expenses, whether or not the Contemplated Transactions are consummated.
6.2.Tax Matters.
6.2.1.Any Transfer Taxes shall be borne and paid fifty percent (50%) by Buyer and fifty percent (50%) by Seller provided, that any Transfer Taxes that are fully refundable or creditable to a particular Person shall be borne exclusively by such Person. The Person required by applicable Law to file a Tax Return relating to Transfer Taxes and pay any Transfer Taxes shall do so within the time period prescribed by applicable Law. If Seller remits to the appropriate Governmental Authority a payment for any Transfer Taxes (including as a result of an audit or examination of Seller), Buyer shall promptly reimburse Seller for the full amount of Transfer Taxes paid by Seller to the Governmental Authority. Buyer and Seller shall, and shall cause their respective affiliates to, cooperate in connection with the filing of any Tax Return for Transfer Taxes including joining in the execution of such Tax Return for Transfer Taxes and in obtaining all available reductions in or exemptions from such Transfer Taxes.
6.2.2.After the Closing, upon reasonable request and without limiting the other provisions of the this Agreement, Buyer, on the one hand, and Seller, on the other hand, agree to furnish or cause to be furnished to each other and their Representatives reasonable cooperation with respect to Tax matters pertaining to the Purchased Assets and the Assumed Liabilities including the furnishing or making available of records, personnel, or other materials reasonably necessary for the preparation or filing of Tax Returns or the defense of an audit, examination, judicial or administrative proceeding; provided, however, that this Section 6.2.2 shall not require any Party to share its or its Affiliates’ Tax Returns with the other Party.
6.2.3.In the case of any Straddle Period, the amount of any property, ad valorem or similar Tax in respect of the Purchased Assets or the Assumed Liabilities shall be apportioned between the portion of such Straddle Period included and the Pre-Closing Tax Period and the remainder of such Straddle Period by allocating such Taxes on a daily basis for each day in the entire Straddle Period.
6.2.4.Unless the relevant action is expressly required by applicable Law, following the Closing, except as consented to by Seller (such consent not to be unreasonably withheld, conditioned or denied), Buyer shall not, and shall not permit its Affiliates to, (i) file any Tax Returns or amended Tax Returns which relate exclusively to the Purchased Assets or the Assumed Liabilities for a Pre-Closing Tax Period, (ii) take any action with respect to the Purchased Assets or the Assumed Liabilities on the Closing Date, but after the Closing, outside the ordinary course of business or (iii) initiate or enter into any voluntary disclosure agreement or similar program for Taxes with any Governmental Authority that relates to t the Purchased Assets or the Assumed Liabilities for a Pre-Closing Tax Period, in each case, if the applicable action would be reasonably expected to (A) increase the Taxes of Seller or (B) increase the amount of the indemnification obligations of Seller under Section 7.2.1 with respect to Taxes.



6.2.5.Except as otherwise required by applicable Law, Buyer and Seller shall, and shall cause their respective Affiliates to, treat any Earn-Out Payments under Section 3.5 and any indemnification payments made pursuant to Article 7 as adjustments to the aggregate consideration paid by Buyer for the Purchased Assets for applicable Tax purposes.
6.3    Confidentiality.
6.3.1.Seller agrees that, from and after the Closing, all non-public information included in the Purchased Assets and any other non-public information related to the Purchased Assets or the Assumed Liabilities other than information belonging to a Third Party is deemed to be confidential information of Buyer (“Confidential Information”) and Seller shall keep confidential and not disclose to any Third Party or use any such information; provided that Seller may use or disclose the Confidential Information (a) for the purpose of complying with or enforcing Seller’s rights, covenants and obligations under this Agreement or any other Transaction Document and (b) in connection with Seller’s defense against, or prosecution of, any Action relating to the Business or the Purchased Assets, including the defense against or prosecution of any Action relating to (i) the ownership of the Purchased Assets prior to the Closing, (ii) the Assumed Contracts with respect to any period prior to the Closing or (iii) the operation or conduct of the Business prior to the Closing.
6.3.2.Seller agrees, from and after the Closing, to enforce all rights of Seller in connection with any obligation of any current or former employees, independent contractors or consultants of the Business owed to Seller to refrain from competing with all or any portion of the Business or disclosing any Confidential Information or other non-public or proprietary information of the Business.
6.4.Cooperation in Litigation Matters. Each Party agrees to, after the Closing, reasonably cooperate with the other Party and any of the other Party’s Affiliates in connection with the defense by such requesting Party or any of its Affiliates against, or the prosecution of, any Action commenced by a Third Party relating to the Purchased Assets or the Assumed Liabilities, including by permitting the Representatives of such requesting Party (including legal counsel and accountants) to (a) have reasonable access at reasonable times, and in a manner so as not to interfere with the normal business operations of the other Party, to the other Party and its Representatives and to the books, records, contracts and documents included in the Purchased Assets or the Assumed Liabilities or otherwise to the extent relating to the Purchased Assets or the Assumed Liabilities and (b) make copies of any of the items described in clause (a).
6.5.Escrow Agreement. Following the Closing, and within the time frame(s) agreed by each of Givaudan and Firmenich, each of Buyer and Seller shall deliver the Escrow Agreement, duly executed by such party.
6.6.Conduct of the Business. Following the Closing, Seller will not enter into any Contracts related to the Business, the Molecules or the Future Molecules (as defined in the License Agreement) with any of Givaudan, Firmenich or Takasago or any of their respective Affiliates without the prior written consent of Buyer, which shall not be unreasonably withheld, except as it may relate to existing Firmenich research and development of the Molecules, and to the extent related to Firmenich, the Future Molecules (as defined in the License Agreement) or intellectual



property matters and in each case, subject to the confidentiality obligations imposed on Seller by Givaudan and Firmenich.
ARTICLE 7
INDEMNIFICATION
7.1.Survival. All of the representations, warranties and covenants contained in this Agreement (other than the representations and warranties set forth in Section 4.1, Section 4.9 and Section 5.1) shall survive the Closing until the twelve-month anniversary of the Closing Date. The representations and warranties set forth in Section 4.1, Section 4.9 and Section 5.1 shall survive until the six-year anniversary of the Closing Date. Notwithstanding the foregoing (a) any obligation to indemnify, defend and hold harmless pursuant to this Article 7 shall not terminate with respect to any item as to which the Indemnified Party shall have, before the expiration of the applicable survival period, previously made a claim by delivering a written notice of such claim to the Indemnifying Party in accordance with Section 7.4 and (b) nothing in this Section 7.1 shall be deemed to limit the survival of, or the ability of any Party to make a claim arising out of, any covenant or agreement of any Party that by its terms contemplates or requires performance after the Closing or that is set forth in this Article 7 (including Section 7.2.1(b) and Section 7.2.2) or Article 8.
7.2.Indemnification.
7.2.1.From and after the Closing, Seller shall indemnify and hold harmless Buyer, its Affiliates and its and their respective Representatives and controlling persons with respect to:
(a)any and Losses resulting from, arising out of or related to any breach or inaccuracy in any of the representations or warranties made by Seller in Article 4 of this Agreement;
(b)any and all Losses resulting from, arising out of or related to any Excluded Liability; and
(c)any compensation that may become payable to [*] in connection with Amendment 2, [*] of the Firmenich Collaboration Agreement and [*] of the Firmenich Supply Agreement.
7.2.2.From and after the Closing, Buyer shall indemnify and hold harmless Seller and its Representatives and controlling persons with respect to any and all Losses resulting from, arising out of or related to any Assumed Liability or the portion of the Transfer Taxes that are the responsibility of Buyer under Section 6.2.1 (excluding any Losses to the extent resulting from, arising out of or related to (a) a breach or inaccuracy in any of the representations or warranties made by Seller in Article 4 of this Agreement (assuming solely for this purpose that such representations and warranties survive the Closing indefinitely) or (b) Seller’s breach of any of its covenants set forth in this Agreement).
7.3 Claims Procedure.
7.3.1.In the event that Seller or Buyer should have a claim against the other Party under this Article 7, the Party seeking indemnification (the “Indemnified Party”) shall, as promptly as



reasonably practicable after discovery of such claim, deliver written notice of such claim to the other Party (the “Indemnifying Party”). The failure by the Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability that it may have to such Indemnified Party under this Article 7, except to the extent that the Indemnifying Party demonstrates that it has been actually prejudiced by such failure.
7.3.2.If an Indemnified Party receives notice or otherwise learns of the assertion by any Third Party of any claim or demand or of the commencement by any Third Party of any Action as to which an Indemnifying Party may be obligated to provide indemnification pursuant to this Agreement (a “Third Party Claim”), the Indemnified Party shall notify the Indemnifying Party of the Third Party Claim in writing and in reasonable detail describing the basis for any claim for indemnification hereunder and including copies of all notices and documents received by the Indemnified Party from Third Parties relating to the Third Party Claim (subject to any bona fide claims of attorney-client privilege) promptly (and in any event within thirty (30) days after receipt by such Indemnified Party of written notice of the Third Party Claim); provided, however, that the failure to provide notice of any such Third Party Claim pursuant to this sentence shall not relieve the Indemnifying Party from any liability that it may have to such Indemnified Party under this Article 7, except to the extent that the Indemnifying Party demonstrates that it has been actually prejudiced by such failure. Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, promptly (and in any event within five (5) business days) after the receipt thereof by the Indemnified Party, copies of any and all additional written notices and documents (including court papers) received by the Indemnified Party from Third Parties relating to the Third Party Claim, subject to any bona fide claims of attorney-client privilege.
7.3.3.The Indemnifying Party has the right, exercisable by written notice to the Indemnified Party within thirty (30) days after receipt of notice from the Indemnified Party, to assume and conduct the defense (including settlement) of such Third Party Claim in accordance with the limits set forth in this Agreement with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. If the Indemnifying Party does not assume the defense of a Third Party Claim in accordance with this Section 7.3.3, the Indemnified Party may continue to defend the Third Party Claim. If the Indemnifying Party has assumed the defense of a Third Party Claim as provided in this Section 7.3.3, the Indemnifying Party shall not be liable for any legal expenses subsequently incurred by the Indemnified Party in connection with the defense of the Third Party Claim. The Indemnifying Party, if it has assumed the defense of any Third Party Claim as provided in this Agreement, may not, without the prior written consent of the Indemnified Party, consent to a settlement or compromise of, or the entry of any judgment arising from, any such Third Party Claim that (a) does not include as an unconditional and irrevocable release of the Indemnified Party from all Liability in connection with the Third Party Claim, (b) provides for injunctive or other nonmonetary relief affecting the Indemnified Party or any of its Affiliates, (c) involves any finding or determination of wrongdoing or violation of Law by the Indemnified Party or any of its Affiliates, or (d) in the reasonable opinion of the Indemnified Party, would otherwise materially used adversely affect the Indemnified Party or any of its Affiliates. The Indemnified Party may consent to a settlement or compromise of, or the entry of any judgment arising from, any Third Party Claim, the defense of which has not been assumed by the Indemnifying Party, only with the prior written consent of the Indemnifying Party, not to be unreasonably withheld, conditioned or delayed.



7.4.Buyer’s Off-Set Right. Buyer shall have the right to deduct from and off-set against any Earn-Out Payment the amount of any Losses payable by Seller or any of its Affiliates pursuant to Section 3.5.4, Section 3.5.5, Section 3.5.6 or this Article 7 that have not been paid prior to the date of such Earn-Out Payment.
ARTICLE 8
GENERAL
8.1.Public Statements. Neither of the Parties shall issue or cause the publication of any press release or other public announcement with respect to this Agreement or the Contemplated Transactions without consulting with and obtaining the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that such consent shall not be required where such release or announcement is required by Law (including disclosure requirements as may be applicable with respect to securities exchanges on which securities of a Party or its Affiliate are traded; provided, that the Parties shall use commercially reasonable efforts to consult with the other Party prior to any such release or announcement).
8.2.Notices. All communications, notices and consents provided for herein shall be in writing and given in person, by electronic mail, by nationally recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested), and shall become effective: (a) on delivery if given in person; (b) on the date of transmission if sent by electronic mail and the sender does not receive a delivery failure message; (c) one (1) Business Day after sending by a nationally recognized overnight courier delivery service; or (d) four (4) Business Days after being mailed, with proper postage and documentation, for first-class registered or certified mail, prepaid.
Notices shall be addressed as follows (provided that if a Party shall have designated a different address by notice to the other Party delivered pursuant to this Section 8.2, then notices shall be addressed to the last address so designated):
8.2.1.if to Seller:
Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
Attention: Nicole Kelsey, General Counsel
E-mail:
8.2.2.if to Buyer:
DSM Nutritional Products Ltd.

Attention:
E-mail:
with a copy to (which copy shall not constitute notice):
Latham & Watkins LLP
330 North Wabash Avenue



Suite 2800
Chicago, IL 60611
Attention: Shaun D. Hartley; Jason Morelli
E-mail:
8.3.Amendment; Waiver; Cumulative Rights.
8.3.1.Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by or on behalf of each of Buyer and Seller.
8.3.2.Waiver. Failure or delay by either Party in exercising or enforcing any provision, right, or remedy under this Agreement, or waiver of any remedy hereunder, in whole or in part, shall not be deemed a waiver thereof, or prevent the subsequent exercise of that or any other rights or remedy. Any of the terms, covenants, representations, warranties or conditions in this Agreement may be waived only by an instrument in writing signed by or on behalf of the Party waiving such compliance.
8.3.3.Cumulative Rights. Except where otherwise expressly provided herein, the rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.
8.4.Assignment. The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns; provided that this Agreement may not be assigned by either Party without the prior written consent of the other Party, except that Buyer may freely assign any or all rights under this Agreement, without the prior written consent of Seller, (a) to one of its Affiliates, (b) as collateral to any person providing debt financing to Buyer or its Affiliates or (c) if such assignment occurs in connection with a sale of all or substantially all of its assets to which this Agreement relates, regardless of whether such sale is structured as an asset sale, merger, reorganization or similar transaction; provided, further, that no assignment shall relieve the assigning Party of any of its obligations under this Agreement. Any attempted assignment, transfer or delegation in violation of the foregoing shall be null and void.
8.5.Entire Agreement. This Agreement, together with the other Transaction Documents, constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof, and cancels and supersedes all other prior agreements, arrangements, understandings and undertakings, both written and oral, between the Parties with respect to the subject matter of this Agreement and the other Transaction Documents.
8.6.Governing Law; Jurisdiction; Waiver of Jury Trial.
8.6.1.This Agreement and the other Transaction Documents shall be governed in all respects, including validity, interpretation, construction, performance and effect, by the internal laws of the State of New York, without reference to choice of law principles that would result in the application of the law of any other state or jurisdiction. The Parties agree that the federal or state courts located in the State of Delaware or any appellate court therefrom (the “Designated Courts”) shall have exclusive jurisdiction over any dispute or controversy arising out of or relating to this Agreement, the other Transaction Documents or any of the Contemplated



Transactions. Each of the Parties waives any defense of inconvenient forum to the maintenance of any Action or proceeding so brought.
8.6.2.EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY CONTEMPLATED TRANSACTION. EACH PARTY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD SEEK TO AVOID THE FOREGOING WAIVER IN THE EVENT OF LITIGATION AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.6.2.
8.7.Counterparts; Effectiveness; Third Party Beneficiaries. This Agreement may be executed in two or more counterparts which together shall constitute a single agreement. Any counterpart may be signed and transmitted by facsimile or electronic mail (including in PDF or similar format) with the same force and effect as if such counterpart was an ink-signed original. This Agreement shall become effective when each Party shall have received a counterpart hereof signed by the other Party. No provision of this Agreement, except Sections 8.6 and 8.12 with respect to Non-Recourse Parties, is intended to confer any rights, benefits, remedies, obligations or Liabilities hereunder upon any Person other than the Parties and their respective successors and permitted assigns.
8.8.Representation by Legal Counsel. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions.
8.9.Section Headings; Construction. The headings of Sections in this Agreement are provided for convenience only and will not affect its construction or interpretation. All references to “Section” or “Sections,” “Article” or “Articles” refer to the corresponding Section or Sections, or Article or Articles, of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the words “including” or “includes” do not limit the preceding words or terms and shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” The word “or” when used in this Agreement is not exclusive. The word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if.” All Exhibits and Schedules annexed hereto or referred to herein are incorporated in and made a part of this Agreement as if set forth in full herein. References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.



8.10.Validity. If any provisions of this Agreement shall be held to be illegal, invalid or unenforceable under any Law, then such contravention or invalidity shall not invalidate the entire Agreement. Such provision shall be deemed to be modified to the extent necessary to render it legal, valid and enforceable, and if no such modification shall render it legal, valid and enforceable, then this Agreement shall be construed as if not containing the provision held to be invalid, and the rights and obligations of the Parties shall be construed and enforced accordingly.
8.11.Specific Performance. The Parties agree that irreparable damage would occur and that the Parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that each Party shall be entitled to an injunction or injunctions to prevent breaches of, and to enforce specifically, this Agreement and the terms and provisions hereof, in the applicable Designated Court, this being in addition to any other remedy to which such Party is entitled at law or in equity.
8.12.Non-Recourse.
8.12.1.This Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement may only be brought against, the entities that are expressly named as Parties hereto and then only with respect to the specific obligations set forth herein with respect to such Party. Except to the extent a named Party to this Agreement (and then only to the extent of the specific obligations undertaken by such named Party in this Agreement), no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, lender, agent, attorney or other Representative of any Party hereto or any Affiliate, successor, heir or assignee of any of the foregoing (each, a “Non-Recourse Party”) shall have any Liability (whether in contract or in tort, in law or in equity, or based upon any theory that seeks to impose liability of an entity party against its owners or Affiliates) for any obligations or Liabilities of any Party under this Agreement or for any claim based on, in respect of, or by reason of, the Contemplated Transactions or in respect of any oral representations made or alleged to have been made in connection herewith.
8.12.2.The provisions of this Section 8.12 are intended to be for the benefit of, and enforceable by, the Non-Recourse Parties, and each such Non-Recourse Party shall be a third party beneficiary of this Section 8.12.
[Remainder of page intentionally left blank; signatures appear on following page.]



IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.
BUYER:
DSM NUTRITIONAL PRODUCTS LTD.

By: /s/ Michael Wahl
Name: Michael Wahl
Title: VP
By: /s/ Bruno Muller
Name: Bruno Muller
Title: VP
SELLER:
AMYRIS, INC.
By: /s/ John Melo    
Name: John Melo
Title: President and CEO
IMAGE_01.JPG

Execution Version
Exhibit 10.02
AMENDMENT NO. 5 TO
SUPPLY AGREEMENT
This Amendment No. 5 to the Supply Agreement (this “Amendment”) is entered into as of March 31, 2021, between DSM Nutritional Products AG, Wurmisweg 576, 4303 Kaiseraugst, Switzerland, (hereinafter “DSM”) and Amyris, Inc., 5885 Hollis Street, Emeryville, CA 94608, USA (hereinafter “Amyris”) (each of DSM and Amyris hereinafter referred to as a “Party”, together referred to as the “Parties”).
WHEREAS, Amyris entered into a Supply Agreement, dated as of December 28, 2017, with DSM Produtos Nutricionais Brasil S.A. (the “Agreement”);
WHEREAS, On January 12, 2018, DSM’s affiliate DSM Produtos Nutricionais Brasil S.A. assigned all of its rights, title and interest in the Agreement to DSM;
WHEREAS, On November 19, 2018 the Parties entered into Amendment No. 1, on April 16, 2019 the Parties entered into Amendment No. 2, on September 30, 2019 the Parties entered into Amendment No. 3 to the Agreement and on December 20, 2020 the Parties entered into Amendment No. 5;
WHEREAS, the Parties desire to further amend the Agreement; and
NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1.Amendments.
a.Section 1.1 of the Agreement is hereby amended to include the following definition: “Takasago Contract” shall mean the Farnesene Supply Agreement between Amyris and Takasago International Corporation, dated December 18, 2015.
b.Section 2.3 of the Agreement is hereby amended and restated (solely to include a reference therein to the “Takasago Contract”) and shall read in its entirety as follows:
Upon the Effective Date, Amyris will provide to DSM a product forecast for the calendar year 2018 (each, a “Product Forecast”). Thereafter, by the fifteenth (15th) business day of the first month of each new quarter, Amyris will provide to DSM a rolling quarterly forecast that consists of four (4) calendar quarters for any Product, which notice shall indicate the Product and the desired volume and completion date, together with any other information reasonably necessary for DSM to carry out such production. DSM shall carry out the Services in accordance with each such notice by Amyris so long as the forecast (i) does not exceed the capacity of the Facility; (ii) change is provided more than ninety (90) days in advance and; (iii) subject to DSM’s obligations to honor the terms of the Takasago



Contract, Vitamin E Contract and the Givaudan Contract. Furthermore, DSM will use reasonable efforts to deliver on any changes to the production forecast that are provided by Amyris less than ninety (90) days in advance. It is agreed by the Parties, however, that (i) where DSM is not reasonably able to decrease production with less than ninety (90) days’ prior notice, Amyris will be bound to purchase the original amount it projected for such period, and (ii) where DSM is not reasonably able to increase production with less than ninety (90) days’ prior notice, it shall not be required to provide to Amyris more than the original amount of Product(s) Amyris projected for such period. It is further agreed that Amyris shall be required to purchase all quantities of Non-Farnesene Products that DSM may produce for Amyris in response to a Product Forecast from Amyris. Amyris shall provide DSM with Product Strain(s) in amounts reasonably required to carry out such Services, as well as the then-current version of applicable Amyris Protocols.
2.Effective Date. This Amendment shall become effective as of March 31, 2021.
3.No Other Amendments. Except as expressly amended hereby, the terms and conditions of the Agreement shall remain unchanged and in full force and effect, and the execution of this Amendment is not a waiver by either Party of any of the terms or provisions of the Agreement. In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall govern. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement. For clarity, any cross-references to Agreement Sections refer to those Agreement Sections as amended by this Amendment.
4.Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same document.
IMAGE_02.JPG


IN WITNESS WHEREOF, DSM and Amyris have caused this Amendment to be executed as of the date first written above by their respective officers thereunto duly authorized.
DSM NUTRITIONAL PRODUCTS AG
By: /s/ Michael Wahl    
Name: Michael Wahl
Title: VP
DSM NUTRITIONAL PRODUCTS AG
By: /s/ Bruno Muller    
Name: Bruno Muller
Title: VP
AMYRIS, INC.

By: /s/ John Melo    
Name: John Melo
Title: President and CEO



Exhibit 31.01

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, John G. Melo, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2021
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer

1


Exhibit 31.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(c) and 15d-(14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Han Kieftenbeld, certify that:

    1.    I have reviewed this Quarterly Report on Form 10-Q of Amyris, Inc.;

    2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

    5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2021
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer

1


Exhibit 32.01

Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, John G. Melo, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2021 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2021
/s/ John G. Melo
John G. Melo
President and Chief Executive Officer
(Principal Executive Officer)

1


Exhibit 32.02

Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Amyris, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Han Kieftenbeld, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge,

(i) the Quarterly Report of the Company on Form 10-Q for the quarterly period ended March 31, 2021 (the “Report”), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2021
/s/ Han Kieftenbeld
Han Kieftenbeld
Chief Financial Officer
(Principal Financial Officer)



1